



## DECRETO DIRIGENZIALE

G025\_2025 Procedura telematica aperta ex art. 71 d.lgs 36/2023 per l'affidamento della fornitura di uno strumento per imaging di vescicole extracellulari di dimensione compresa tra i 50 ed i 150 nm attraverso l'utilizzo di un microscopio super-resolution da destinare all'allestimento del laboratorio del Dipartimento di Scienze Biomediche Sperimentali e Cliniche "Mario Serio" aggiudicato in base al criteri dell'offerta economicamente più vantaggiosa, ai sensi dell'art. 108 lettera c del d.lgs. 36/2023. importo complessivo dell'appalto € 295.000,00 oltre iva di legge; oneri per la sicurezza da interferenze non soggetti a ribasso: € 0,00. CPV 38510000-3 - PROGETTO: GALLIECRF\_EXACTCORE25 finanziato dalla Fondazione CRF CUP B13C25001000007 - CUI F01279680480202400040 - - CIG B7E1373CB7 - DECRETO DI NOMINA COMMISSIONE GIUDICATRICE EX ART. 93 D.LGS. 36/2023.

*Il Dirigente,*

VISTO il d.lgs. n. 36/2023 recante "*Codice dei contratti pubblici*" e relativi allegati;

VISTO lo Statuto dell'Università degli Studi di Firenze;

VISTO il Regolamento di Amministrazione, Finanza e Contabilità dell'Università degli Studi di Firenze;

VISTO il d.lgs. 165/2001 e ss.mm.ii.;

VISTA la normativa vigente in materia di anticorruzione e trasparenza, il Piano Triennale per la Prevenzione della Corruzione e della Trasparenza dell'Università degli Studi di Firenze e il Decreto rettoriale del 8 febbraio 2016, n. 98 - Codice di comportamento dell'Università degli Studi di Firenze;

RICHIAMATA la Decisione di contrarre Rep. n. 1610/2025 Prot. n. 0178244 del 01/08/2025 pubblicata all'Albo n. 9940 Prot. 0178258 del 01/08/2025, con cui è stata indetta la procedura in oggetto da aggiudicare con il criterio dell'offerta economicamente più vantaggiosa, ai sensi dell'art. 108 del d.lgs. 36/2023; in esecuzione della Decisione di contrarre in data 01/08/2025 è stata pubblicata sul sistema telematico START la procedura ID 030265/2025, in oggetto, con scadenza per la presentazione delle offerte al 21/09/2025 ore 12:00.



DATO ATTO che alla scadenza del termine risultava presentata solo una candidatura;

RICHIAMATI il verbale di gara rep. n. 33/2025 prot. n. 0255871 del 23/09/2025 relativo alla fase di apertura e valutazione della busta amministrativa;

CONSIDERATO l'esito positivo del soccorso istruttorio, trasmesso tramite Piattaforma Start, alla Società che ha presentato offerta, con nota prot. n. 0255965 del 23/09/2025;

RILEVATA la necessità di provvedere alla nomina della commissione tecnica preposta all'esame dell'offerta, da costituirsi con un numero di n. 3 componenti esperti nella materia oggetto del contratto;

VALUTATA la qualificazione, anche mediante esame degli allegati *curricula*, dei seguenti soggetti ai fini della nomina a componente della Commissione Giudicatrice:

- Prof.ssa Michaela Luconi afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (Presidente);
- Dott. Massimo D'Amico afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (commissario);
- Dott.ssa Serena Pillozzi afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (commissario);

RITENUTO OPPORTUNO nominare segretario verbalizzante la Dott.ssa Maria Concetta Di Leonardo - Funzionario Amministrativo - e segretario supplente la Dott.ssa Maria Luce Leonessi - entrambe afferenti alla Centrale Acquisti, Università degli Studi di Firenze;

RICEVUTA la disponibilità dei suddetti allo svolgimento dell'incarico;

ACQUISITE le dichiarazioni (conservate agli atti) dei nominandi commissari da cui risulta, con riferimento all'operatore economico che ha rimesso offerta, che non sussistono cause di conflitto d'interesse e di incompatibilità ai sensi della normativa vigente;

RITENUTO di dare attuazione alle disposizioni legislative di cui all'art. 28 co.2 del d.lgs. 36/2023, mediante pubblicazione del presente provvedimento e dei curricula allegati prodotti dai membri della Commissione Giudicatrice, sul profilo del committente Unifi, nella sezione Amministrazione Trasparente - Bandi di gara e contratti, nonché sull'Albo on line della stazione appaltante;

DATO ATTO che tutti gli atti della presente procedura di gara, oltre che sul sistema telematico START e sul profilo committente, sono disponibili anche presso l'Ufficio Centrale Acquisti dell'Università degli Studi di Firenze, via Capponi n.7, primo piano;



cioè premesso,

DECRETA

- a) la nomina, ai fini della valutazione dell'offerta presentata, relativa all'affidamento della fornitura in oggetto, della seguente Commissione Giudicatrice, ai sensi dell'art. 93 d.lgs. 36/2023:
  - Prof.ssa Michaela Luconi afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (Presidente);
  - Dott. Massimo D'Amico afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (commissario);
  - Dott.ssa Serena Pillozzi afferente al Dipartimento di Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio' (commissario);
- b) le attività di segretario verbalizzante saranno svolte dalla Dott.ssa Maria Concetta Di Leonardo - Funzionario Amministrativo, afferente alla Centrale Acquisti; Segretario supplente: Dott.ssa Maria Luce Leonessi - Università degli Studi di Firenze, afferente alla Centrale Acquisti, Università di Firenze;
- c) nessun compenso è dovuto per le attività di cui al presente Decreto;
- d) la pubblicazione del presente provvedimento e relativi *curricula* sul profilo del committente nella sezione bandi di gara, nonché sull'Albo on line della stazione appaltante, ai sensi e per gli effetti dell'art. 28 co.2 del d.lgs. 36/2023.

Il Dirigente

Dott. Massimo Benedetti

Allegati:

1. Curricula Commissari

Dichiarazione sostitutiva di certificazione dell'atto notorietà  
Ai sensi dell'art. 47 DPR 445 del 28.12.2000

La sottoscritta MICHAELA LUCONI, nata a F

[REDACTED]  
consapevole delle responsabilità penali cui può andare incontro conseguenti a dichiarazioni mendaci, ai sensi e per gli effetti di cui all'art. 76 del DPR 445/2000, e consapevole che, ai sensi dell'art. 13, del Regolamento UE 2016/679 (GDPR), la presente dichiarazione sarà pubblicata sul sito web dell'amministrazione in apposita sezione di Amministrazione Trasparente sotto la propria responsabilità

dichiara

ai sensi degli artt. 46 e 47 del DPR 445/2000

**PERSONAL INFORMATION**

Michaela Luconi

 XXXXXXXXXXXXXXX XXXXXXXX XXXXXXXXX  XXXXXXXXXX

Date of birth: XXXXX | Place of Birth: XXXX | Nationality: Italiana  
Family status XXXX

**Employment** Full Professor in Advanced Medical and Surgical Technology and Methodology  
SSD MEDS26D University of Florence SSD MEDS-26D



Head of Research Laboratory: The Biology of the adipose organ & of the adrenal tumours  
adrenal tumors (SBSC-UNIFI) [www.sbsc.unifi.it/vp-232-gruppo-luconi](http://www.sbsc.unifi.it/vp-232-gruppo-luconi)

Orcid number ID 0000-0001-5186-064X Scopus ID 7003464354

Research ID K-6693-2016

**PROFILE**

Prof. Michaela Luconi (Firenze 28.06.1968) is a biologist (MSc in Biology, 1993), PhD in Endocrinology and Metabolism (1999), with expertise in cell biology, endocrinology and cancer. As Associate Professor (from 2005) and Full Professor (from 2020) in translational medical sciences at the University of Florence (Dept. Experimental & Clinical Biomedical Sciences), she currently directs the Laboratory "The biology of the adipose organ & of the adrenal tumors-LABAD". Her research expertise is mainly applied to translational and clinical research in cancer and metabolic pathologies. She is mainly interested in the cellular and molecular basis of endocrine tumors, particularly of adrenal cortical carcinoma, with specific focus on the study of tumor microenvironment and its potential as therapeutic target. Her group works on in vitro cell 2D and 3D complex cell models and on tumor tissues/biological fluids of patients (liquid biopsy, circulating tumor cells and circulating free nucleic acids, DNA, miR), in particular in adrenal tumors to identify novel oncomarkers.

In addition, her expertise and interests are also focused on elucidating the mechanism of metabolic dysfunctions at cell and organ levels, establishing human cellular and tissue models of metabolic dysfunctions related to adipose tissue, such as obesity, insulin resistance and diabetes, with particular interest in organ stem cells.

In the past, during her PhD, she worked in the field of physiopathology of reproduction and of the male gamete, contributing to clarify the molecular mechanisms underlying some pathologies associated with infertility.

Head of Laboratory: The biology of the adipose organ & of the adrenal tumours (SBSC-UNIFI)

[www.sbsc.unifi.it/vp-232-gruppo-luconi.html](http://www.sbsc.unifi.it/vp-232-gruppo-luconi.html)

**Main fields of interest in research and main achievements in the field of endocrinology and cancer:**

1. The biology of the adrenal tumors: cell and clinical models for the development of novel cancer biomarkers
2. Models of metabolic interaction between tumors and tumor microenvironment
3. The liquid biopsy and circulating tumor cells as diagnostic/prognostic and monitoring factors in endocrine tumors
4. Pathophysiology of the adipose organ and of the metabolic disorders
5. Stem cells in the adipose lineage: white, brown and beige fat
6. Cell and tissue in vitro human models of adipose system (subcutaneous, visceral, brown fat)
7. Pharmacological and cellular mechanisms of anti-diabetic drugs (GLP-1 analogues and SGLT inhibitors).

**SCIENTIFIC METRICS**

Number of Publications (peer reviewed): 177 Papers (Scopus); 22 Book Chapters; 2 patents

Total Impact Factor: 978 (2024); Mean 5.85

H-index 2024: 55 (Scopus) 64 (Google Scholar)

Citations: 7748 (Scopus) 10696 (Google Scholar)

27 first, 54 last authorship/correspondence; 35 review; 4 editorials

<https://www.scopus.com/authid/detail.uri?authorId=7003464354>

[https://scholar.google.com/citations?hl=it&user=3Hq9\\_pUAAAAJ](https://scholar.google.com/citations?hl=it&user=3Hq9_pUAAAAJ)

## SCIENTIFIC NATIONAL ABILITATION

15 october 2018-15 october 2024

### National Scientific Abilitation Professore di I fascia

Settore concorsuale 06/N1 Scienze delle professioni sanitarie e delle tecnologie mediche applicate  
Commissione nazionale per l'ASN settore concorsuale 06/N1, bando 2016-2018

9 june 2014-9 june 2020

### National Scientific Abilitation Professore di I fascia

Settore concorsuale 06/N1 Scienze delle professioni sanitarie e delle tecnologie mediche applicate  
Commissione nazionale per l'ASN settore concorsuale 06/N1, bando 2012

## EDUCATION AND TRAINING

2001-2005

### Postgraduate School Fellow in Human Genetics

Dept. Clinical Pathophysiology/University of Florence/Italy Frequenza Scuola Specializzazione in Genetica Medica Università degli Studi di Firenze

1999

### PhD in Endocrinology and Metabolism

Dept. Clinical Pathophysiology/University of Florence/Italy (nov 1995-nov 1998-X ciclo)

Thesis: Il recettore di membrana per il progesterone: caratterizzazione e attivita' biologica di un nuovo tipo di recettore steroideo non genomico negli spermatozoi umani

1994

### Abilitation to Biologist

150/150

Registry n. AA\_045309

1993

### MSc Degree in Biology (summa cum laude) -5 years Biochemistry/University of Florence/Italy

Thesis: Effetto stimolatorio di un inositolo fosfoglicano sul metabolismo glicolitico in piastrine umane

## WORKING EXPERIENCE

### Current position

1<sup>st</sup> March 2020 -

Full Professor of Advanced Medical and Surgical Technology and Methodology SSD MEDS-26D (ex MED/50)  
Dept. Experimental & Clinical Biomedical Sciences  
University of Florence

### Previous positions

Feb 2005-feb 2020

Associate Professor of Applied Medical Sciences SSD MED/50  
Dept. Experimental & Clinical Biomedical Sciences  
University of Florence

Feb 2005-Feb 2020

Referent Biologist Endocrine Diagnostic Laboratory: Genetics of adrenal tumor and paragangliomas; steroid hormone analysis in mass spectrometry/Careggi Hospital (AOUC)/Florence/Italy

2019-2020

Referent of the SOD of Endocrinology Laboratory for Quality & Security (Q&S) Careggi Hospital (AOUC)/Florence/Italy

2000-2005

Senior Technician Reproductive Biology/Real Time Diagnostic Service: HbA1c, sex and adrenocortical hormones  
Dept. Clinical Pathophysiology/University of Florence/Italy

1999-2005

PostDoc Researcher in Endocrinology  
Dept. Clinical Pathophysiology/University of Florence/Italy

### Scientific Mobility

2019

Visiting Professor Semmelweis University, Budapest, HU - Prof. Peter Igaz

2018

Visiting Professor Brunel University, London, UK - Prof. Emmanouil Karteris

2016

Visiting Professor Warwick University, Warwick, UK – Prof. Ponnusamy Saravanan

2014

Visiting Professor ERASMUS PLACEMENT PhD School Technisch Universität Dresden-Germany- Prof. T.Chavakis

2014

Visiting Professor Helmholtz Zentrum München-Germany-Prof. N. Pellegata

2013

Visiting Professor Technisch Universität Dresden-Germany-Prof. T.Chavakis

2013

Visiting Professor University of Barcelona-Spain-Prof. F. Villarroya

2002

Visiting Fellow University Mendoza, Argentina-Prof. M.Fornes

- 2001 Visiting Fellow University Pennsylvania Medical Center, Philadelphia, USA-Prof.. G.Kopf  
 1998 Visiting Fellow Centre for Reproductive Medicine, Bruxelles, BE-Prof. P.Devroy  
 1998 Visiting Fellow EMBL Heidelberg/Germany-Prof. F.Gannon

**Institutional Responsibilities**

- 2024-today Scientific and Internal Audit Committee Dept. Experimental & Clinical Biomedical Sciences, University of Florence
- 2024-today Board Centro di Ricerca CITMQSA (Centro Interdipartimentale delle Tecnologie dei Microsistemi per la Qualità e Sicurezza Ambientale)
- 2023-today Referent of the Dept for the Technology Transfer Programs at University of Florence
- 2021-today Teaching Committee Dept. Experimental & Clinical Biomedical Sciences, University of Florence
- 2021-today Scientific Referent of the Florence ENS@T Center of Excellence
- 2020-today Referent of the Pathophysiology Section of Dept. Experimental & Clinical Biomedical Sciences, University of Florence
- 2020-today Referent of the Repository of biological samples of the European Network for the Study of Adrenal Tumours (ENS@T)
- 2018-today Referent of the Repository of human adipose cells and adipose tissue-CRI-TE AOU Careggi
- 2018-today Board Master II level "Biologia e Tecnologie della Riproduzione", Coordinator Prof. Elisabetta Baldi, University of Florence
- 2016-2020 Scientific and Internal Audit Committee Dept. Experimental & Clinical Biomedical Sciences, University of Florence
- 2015-today Referent for the School of Medicine of Erasmus Placement Program, University of Florence/Italy Università degli Studi di Firenze
- 2005-today Member of the Collegium for PhD in Biomedical Sciences-Endocrine, Molecular and Regenerative Biotechnologies/University of Florence/Italy
- 2013 Member of the Erasmus Placement Program Panel: Department of Clinical Pathobiochemistry, University of Dresden/Germany PhD/MD Program in Molecular Endocrinology
- 2012-2017 Scientific Committee of the Excellence Center DENOTHE/University of Florence/Italy

**Commissions of Trust**

- 2026-today The European Association for Cancer Research Ambassador
- 2024-today Evaluator of ERA Chair HORIZON WIDERA 2023 TALENTS
- 2021-today Management Committee Cost Action CA20122 - Harmonizing clinical care and research on adrenal tumours in European countries-co-chair WG2
- 2021-today Scientific Committee of the Centro di Ricerca e Innovazione sulle Patologie Surrenali -CRISP-Azienda Ospedaliero-Universitaria Careggi
- 2020-today Executive Committee of the Italian Collegium of Applied Medicine SSD MED/50-MEDS-26D
- 2020-today Regularly serves in Commissions of Evaluation for Researcher positions of Italian Universities in MEDS26
- 2019-today H2020 – Expert group JRC / Joint Research Center for Metabolic diseases
- 2019-today Executive Commission European Network for the Study of Adrenal Tumors ENS@T

2019-today	Referent of the Research Biobank Program Centro di Ricerca ed Innovazione Tissue Establishment (CRI-TE) Azienda Ospedaliero-Universitaria Careggi
2014-2020	Biology Board of the Italian Society Endocrinology
2014-today	VC/Evaluator Marie Skłodowska-Curie Horizon2020: Life Science panel REA
2010-2013	Evaluator for Marie Curie Marie Curie FP7: Life Science panel REA
2013-2018	Scientific Board ENS@T European Society

#### Inter-University Consortia and Joint Laboratories

2023	Scientific Referent of the Joint Laboratory <b>BIODELIVERY</b> between UNIFI and RE-CORD Consortium of research on Renewable Energy-scope: Development and analysis of innovative green systems based on biochar for the release of bioactive molecules in metabolic, inflammatory and tumor diseases affecting the digestive tract and endocrine tumors
2019-today	Member of the inter-university Consortium INBB "Istituto Nazionale Biostrutture e Biosistemi"
2022-today	Centro interdipartimentale di Ricerca per la Valorizzazione degli Alimenti UNIFI-director Prof. Francesco Sofi (CeRA)

#### Commissions for Academy

From 2015	Commissione per Procedura selettiva per Ricercatore, Professore Associato, Professore Ordinario per il settore concorsuale MEDS-26 ex 06/N1 - SCIENZE DELLE PROFESSIONI SANITARIE E DELLE TECNOLOGIE MEDICHE
-----------	--

#### Editorial Board

2022-today	Vitamins & Hormones Academic Press/Elsevier Editorial Board
2019-today	Associate Editor Cancers
2022	Topic Editor for Cancers: Targeting tumor microenvironment as a novel promising approach in adrenal tumors
2019	Topic Editor for Frontiers in Endocrinology "Stem cells in endocrine tumors"
2017-today	Associate Editor International Journal of Endocrinology
2013-today	Associate Editor Frontiers in Endocrinology, Oncology
2012-today	Associate Editor Applied Cell Biology
2009-today	Associate Editor Inflammation & Allergy - Drug Targets
2005-2008	Editorial Board Società Italiana di Andrologia Medica

#### Internationalization Activity Incoming Visiting Professors

April 2023 & May 2025 Prof. Ronald R. De Krjger- Princess Máxima Center for pediatric oncology di Utrecht, NL

June .2022 Prof. Joan Villarroya – University of Barcelona, Spain

June-July 2017 Dr. Enzo Lalli - Université Côte d'Azur and CNRS Sophia Antipolis, Valbonne, France

March-July 2016 Dr. Anthony Scimè - Molecular, Cellular and Integrative Physiology, Faculty of Health, York University, Toronto, Ontario, Canada

#### Incoming International PhD students

Oct 2019-Oct 2020

Diego Assis Gonçalve, PhD Student in Imunologia e Doenças Infecto-parasitárias- Universidade Federal de Juiz de Fora, Brazil

March-Dicember 2020

Carme Grau-Bové, PhD student in MoBioFood Research Group, Universitat Rovira i Virgili-Tarragona (Spain)

#### International Doctoral in Philosophy Commissions

25 July 2025

- External Faculty Examiner of Dr. Sarah Feely dissertation: Cytotoxic Responses and Cell Death Mechanisms in Adrenocortical Carcinoma: Insights into Mitotane and Cisplatin Treatment, University of Galway, Galway, Ireland.  
30 Sept.2021
- External Faculty Examiner of Dr. Carme Grau Bové dissertation for Doctor of Philosophy: Regulation of enteroendocrine function by bioactive components through their interaction with bitter taste receptors", Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain  
16 Sept. 2017
- External Faculty Examiner of Dr. Rajani Maharjan dissertation for Doctor of Philosophy: New Insights in Adrenal Tumorigenesis Faculty of Medicine, Uppsala University, Uppsala, Mentor Prof. Peyman Bjorklund.

#### Congress Organization

- 2026 X Adrenal Cancer Sympisium Brescia-16-18 October
- 2025 Joint 24th ENS@T scientific meeting & 4th Harmonis@tion COST meeting; 3<sup>rd</sup>-5<sup>th</sup> September 2025, Belgrade, Serbia  
8th COST Harmonis@tion Adrenal Tumor Masterclass  
7<sup>th</sup> Cost Harmonisation Adrenal Tumor online Master Class-24-25 March, 2025
- 2024 Joint 23rd ENS@T scientific meeting & 3rd Harmonis@tion COST meeting; 2<sup>nd</sup>-4<sup>th</sup> October 2024, Palma de Maillorca, Spain  
6th COST Harmonis@tion Adrenal Tumor Masterclass  
5<sup>th</sup> Cost Harmonisation Adrenal Tumor online Master Class-15-16 April 2024
- 2023 Joint 22rd ENS@T scientific meeting & 2nd Harmonis@tion COST meeting- 11-13 Oct 2023, Dubrovnik, Croatia  
4th COST Harmonis@tion Adrenal Tumor Masterclass  
3<sup>rd</sup> Cost Harmonisation Adrenal Tumor online Master Class-29 - 31 March 2023
- 2022 Joint 21st ENS@T Scientific Meeting and 1st Harmonis@tion COST meeting-28-30 Sept 2022,Wacraw, Poland  
2<sup>nd</sup> Cost Harmonisation Adrenal Tumor Master Class  
1<sup>st</sup> Cost Harmonisation Adrenal Tumor online Master Class-23 – 25 March 2022
- 2021 Joint 20th ENSAT meeting and 8th International Adrenal Cancer Symposium 2021 e-Congress-30 Sept-2 Oct 2021, Zurich, CH
- 2020 Scientific Committee 19<sup>th</sup> ENS@T Scientific eSymposium - 6 Nov 2020, Zurich, CH
- 2018 Local Organizing Committee 17<sup>th</sup> ENS@T Scientific Meeting - 22-23 Nov 2018, Florence, Italy

#### TEACHING ACTIVITY BSC & MSC

- From 2005 **MSC CdL B121 BIOTECNOLOGIE MEDICHE E FARMACEUTICHE SCUOLA SSU**  
Insegnamento B029437 - ADVANCED BIOTECHNOLOGIES IN MEDICINE-CFU 2.0  
Insegnamento B030329 - METODOLOGIA DELLA RICERCA SCIENTIFICA-CFU 2.0  
Insegnamento B029482 - LABORATORY TECHNIQUES IN SPERMATOLOGY-CFU 0.5
- From 2010 **MSC CdL B184 - SCIENZE DELLE PROFESSIONI SANITARIE DELLA PREVENZIONE SCUOLA SSU**  
Insegnamento B020270 – METODOLOGIA DELLA RICERCA  
Modulo B020273 - SCIENZE TECNICHE MEDICHE APPLICATE-CFU1.0
- From 2010 **MSC CdL B183 - SCIENZE DELLE PROFESSIONI SANITARIE TECNICHE DIAGNOSTICHE SCUOLA SSU**  
Insegnamento B020344 – METODOLOGIA DELLA RICERCA  
Modulo B020348 - SCIENZE TECNICHE MEDICHE APPLICATE-CFU1.0
- From 2024 **MSC CdL 061 – INGEGNERIA BIOMEDICA SCUOLA INGEGNERIA**  
Insegnamento B025355 SCIENZE TECNICHE E MEDICHE APPLICATE -  
Modulo B025351 METODOLOGIA DELLA RICERCA APPLICATA ALLA PREVENZIONE-CFU1.0
- From 2010 **BSC CdL B178 - ASSISTENZA SANITARIA SCUOLA SSU**  
Insegnamento B030105 - METODOLOGIA DELLA RICERCA  
Modulo B030109 - METODOLOGIA DELLA PROFESSIONE DI ASSISTENTE SANITARIO PER LA RICERCA, L'OSSERVAZIONE E L'ANALISI DEI BISOGNI-CFU1.0
- From 2010 **BSC CdL B179 – TECNIHE DELLA PREVENZIONE NELL'AMBIENTE E NEI LUOGHI DI LAVORO SCUOLA SSU**  
Insegnamento B025351-METODOLOGIA DELLA RICERCA APPLICATA ALLA PREVENZIONE -  
Modulo B025355-SCIENZE TECNICHE E MEDICHE APPLICATE-CFU 1.5
- From 2024 **BSC CdL B061 – OSTEOPATIA SCUOLA SSU**  
Insegnamento B034361 METODOLOGIA DELLA RICERCA  
Modulo B034359 STATISTICA MEDICA E METODOLOGIA DELLA RICERCA IN OSTEOPATIA  
Insegnamento B034362 RICERCA IN OSTEOPATIA  
Modulo B034359 STATISTICA MEDICA E METODOLOGIA DELLA RICERCA IN OSTEOPATIA
- From 2024 **CdL B240 – MEDICINA & CHIRURGIA SCUOLA SSU**  
Insegnamento B032853 ATTIVITA' FORMATIVE PROFESSIONALIZZANTI I Biomedical research
- From 2024 Board Comitato della Didattica CdL Osteopatia
- From 2005 Erasmus Referent for International Mobility CdL Biotecnologie Mediche e Farmaceutiche

#### POST-GRADUATE COURSES

- POSTGRADUATE SCHOOL in ENDOCRINOLOGIA E MALATTIE DEL METABOLISMO SCUOLA SSU**  
Insegnamento B024984 - SCIENZE TECNICHE MEDICHE APPLICATE -APPLIED MEDICAL TECHNICAL SCIENCES-CFU 0.5

#### PHD COURSES

- From 2023 **PhD in Biomedical Sciences -indirizzo Tecnologie omiche single cell**  
Università degli Studi di Firenze
- 2005-2022 **Board PhD in Biomedical Sciences -indirizzo Biotecnologie Endocrine, Molecolari e Rigenerative**  
Università degli Studi di Firenze
- PhD in Endocrinology and Metabolism PhD in Biomedical Sciences-indirizzo Biotecnologie Endocrine, Molecolari e Rigenerative-indirizzo Biotecnologie Endocrine, Molecolari e Rigenerative  
Università degli Studi di Firenze
- 2005-2022 **Istituto Universitario di Studi Superiori Ateneo Firenze (IUSSAF)**  
Università degli Studi di Firenze

## Int'nal PhD Programmes

**PhD Course "Genetics and genomics of endocrine tumors"**  
Semmelweis University, Budapest, HU "Studies on CTC in ACC"

**Erasmus Placement Technische Universität Dresden PhD/MD Program in Molecular Endocrinology** "The adipose organ: pathophysiology and molecular biology"

**MASTERS**

**Master II level Andrology, Sexual Medicine and Reproduction** SCUOLA SSU  
Università degli Studi di Firenze (2018-today)

**Master II level Biology & Technology of Reproduction** SCUOLA SSU  
Università degli Studi di Firenze (2018-today)

**Master di I level in Clinical Neuropathophysiology in critical care and intensive care** SCUOLA SSU  
Università degli Studi di Firenze (2018-today)

**Master I levels in Oncology Radiotherapy** SCUOLA SSU  
Università degli Studi di Firenze (2013-2015)

**Master di I level in Andrology**  
Università degli Studi di Firenze (2002-2007)

**Master in Spermatology**  
University Mendoza-Argentina (2002)

**SUPERVISION & MENTORSHIP**

She has been mentoring undergraduate, PhD and Senior scientists since 2005  
13 PhD Students/University of Florence/Italy

2 ERASMUS incoming PhD students:

-Diego Assis Gonçalve, PhD Student in Imunologia e Doenças Infecto-parasitárias- Universidade Federal de Juiz de Fora, Brazil  
-Carme Grau-Bové, PhD student in MoBioFood Research Group, Universitat Rovira i Virgili Tarragona (Spain)

4 resident specialization students Endocrinology & Metabolic Pathologies/University of Florence/Italy

5 Post-doc Students/University of Florence/Italy

4 BSc ERASMUS incoming students: University of Barcelona-Spain; Universidad Lleida-Spain; Istituto Universitario Egas Moniz, CRL, Dipartimento Biomedical Laboratory Sciences Università, Portugal

50 graduating students in Medicine, Biology, Biotechnology (MD, MSc, BSc)

**PHD FELLOWS**  
BIOMEDICAL SCIENCES  
DEPT. CLINICAL AND  
EXPERIMENTAL BIOMEDICAL  
SCIENCES:

**Adriana Lombardi** ciclo XXI-2005/2008 "Studio dei meccanismi molecolari alla base degli effetti pro-infiammatori di TNF $\alpha$  e IFN $\gamma$  e dell'azione anti-infiammatoria dei tiazolidinedioni, in un modello in vitro di cellule endoteliali umane"

**Elisa Borgogni** ciclo XXII-2006/2009 Ipotesi di nuovi approcci farmacologici per il trattamento della malattia di Graves: studio degli effetti anti-infiammatori di agonisti di PPAR $\gamma$  e di analoghi della vitamina D

**Giulia Cantini** ciclo XXIV-2009/2012 "Isolamento e caratterizzazione morfologica e funzionale di cellule mesenchimali staminali adulte da tessuto adiposo umano sottocutaneo e viscerale"

**Giada Poli** ciclo XXVI-2011/2013 "Ricerca di nuovi target terapeutici nel carcinoma corticosurrenale e studio dei meccanismi di azione del farmaco mitotane"

**Alessandra Di Franco** ciclo XXVIII-2012/2015 "Caratterizzazione di nuovi modelli di cellule staminali isolate da tessuto adiposo bruno: il modello umano adulto e il modello fetale"

**Roberta Armignacco** ciclo XXX-2014/2017 "Evolution and progression of adrenocortical carcinoma: the potential role of the adiposemicroenvironment and the isolation and characterization of circulating tumor cells- PhD EUROPEUS"

**Giuseppina De Filpo** ciclo XXXIII-2017/2020 "Feocromocitoma/paraganglioma ed altre neoplasie non cromaffini associate: uno studio multicentrico"

**Martina Trabucco** ciclo XXXIII-2017/2020 "Gli effetti del glucagone e degli agonisti del GLP-1R in un modello di precursori adiposi umani"

**Giovanni Quartararo** ciclo XXXIV-2018/2024 "Do exist specific predictors of outcome in terms of long-term weight-loss after bariatric surgery? Visceral adipose tissue adiponectin and serum triglycerides can predict excess weight loss after bariatric surgery in female subjects with severe obesity."

**Laura Fei** ciclo XXXVII-2022/2024 PhD PON European Union - Next Generation EU " NEW INNOVATIVE ANTI-CANCER APPROACHES: THE POTENTIAL OF BUTYRATE-GLYCERIDES IN COLORECTAL CANCER AND THE INTERACTION OF THE ADIPOSE MICROENVIRONMENT IN HEPATOCELLULAR CARCINOMA"

*Ongoing:*

**Arianna Pia Propato** ciclo XXXVIII-2023/2025 PhD PNRR European Union - Next Generation EU

**Dimitri Papini** ciclo XXXVIII-2023/2025 PhD PNRR European Union - Next Generation EU

**Chiara Lepri** ciclo XL-2024/2027 PhD MUR European Union - Next Generation EU

External revisor for 6 PhD students: University of Brescia, University of Pavia, University of Padova, University of Torino, University of Milano, University of Rome "Foro Italico"

International External Revisor for VIVA:

Sarah

**Undergraduated Students Scientific career of ex graduating students in Prof. Luconi's Lab**

**Dr. Jinous Samavat**, 2019 PhD at Warwick University, UK-currently post-doc senior scientist at Nottingham University, UK (2020-)

**Dr. Gabriele Varano**, PhD FIRC Institute of Molecular Oncology (IFOM) in Milan (S. Casola)- currently Senior Research at IFOM, Milan

**Dr. Martina Tabucco**, PhD UNIFI, Eli Lilly Head of Dulaglutide production (2019-)

**Dr. Roberta Armignacco**, 2017 PhD UNIFI-currently postdoc fellow Cochin Hospital, Paris (Prof. G. Assié) 2017-

## CLINICAL ACTIVITY

2019-2020

Board Quality & Security Referent for the Lab of SOD Endocrinology-DAI Medico-Geriatrico AOU Careggi

2005-2020

Dirigente Biologo Azienda Ospedaliero Universitaria Careggi  
Lab Endocrinology SOD of ENDOCRINOLOGY

Referent for the programs:

- Genetic analysis of adrenal tumors
- Mass spectrometry analysis of steroid hormones
- Development & clinical transferability of new diagnostic and prognostic markers in diabetes (glycated albumin, anidroglucitol, DPPIV activity in patients with diabetes; as well as in adrenal tumors (circulating tumor cells; proteomics of the tumors))
- Development of the translational Unit Translational Medicine "RESEARCH & DEVELOPMENT OF DIAGNOSTIC-PROGNOSTIC TOOLS IN ENDOCRINE AND METABOLIC PATHOLOGIES- SOD di Endocrinologia AOUC

## SCIENTIFIC ACTIVITY

### AWARDS AND INTERNATIONAL RECOGNITIONS

**2024** Best clinical publication award from ENSAT in the topic of Adrenocortical cancer " Cioppi F, Cantini G, Ercolino T, Chetta M , Zanatta L , Nesi G , Mannelli M , Maggi M, Canu L, **Luconi M.**\* Targeted NGS Approach and Its Clinical Application in Adrenocortical Cancer, *Eur J Endocrinol.* 2024 doi: 10.1093/ejendo/lvae077

**2019** INBB XIII Convegno Nazionale INBB "Ricerca e Innovazione per Ambiente, Salute ed Alimentazione, best poster prize

**2013** Endocrine Society, San Francisco, US, platform presentation

- 2011** Prof. Giusti's Award from the Italian Society of Endocrinology  
**2011** European Society of Endocrinology, Rotterdam, NK  
**2009** Endocrine Society ENDO 09, 91<sup>st</sup> Meeting, Washington, US: Presidential poster competition  
**2005** American Society of Andrology, Seattle, US: Lalor Award  
**2005** American Society of Andrology, Seattle, US: Steinberger Award  
**2003** Fellowship Special FEBS Meeting on Signal Transduction 2003, Bruxelles, BE  
**2002** American Society of Andrology- T. Chang Travel Grant-Seattle, US  
**2001** "Tronchetti 2001 Prize" by Schering Foundation: best research in the Italian Endocrine Society  
**2001** American Society of Andrology (ASA): T. Chang Travel Grant-Montreal, Canada  
**2000** International Congress of Endocrinology: Travel Grant to Sydney, Australia  
**2000** Young Researcher Award, University of Florence  
**1999** Premio Borsa studio IPSEN Società Italiana Endocrinologia  
**1999** American Society Study of Reproduction: Burroughs Wellcome Fund & Travel Fellow Prize, Pulmann Washington, US  
**1997** American Society of Andrology: T. Chang Travel Grant-Baltimore, US  
**1996** American Society of Andrology: Student Merit Award  
**1996** Italian Society of Clinical Andrology  
**1995** Borsa Sandoz Società Italiana Endocrinologia  
**1994** Italian Society of Clinical Andrology and Italian Endocrine Society: Award Lecture

**INVITED SPEAKER**

- 2025** ENDO2025 Endocrine Society's Annual Meeting, San Francisco CA, July 12-15, 2025  
Symposium: Assessment of Adrenocortical Carcinoma with Multi-Omics: From Pathogenesis to Prognostification and Personalized Treatment  
"Prognostic factors in adrenocortical carcinoma: the Liquid Biopsy Era"
- 2025** Italian Society of Endocrinology (SIE) 43th National Congress, Turin 11-14 June 2025  
"The Liquid Biopsy in ACC diagnosis"
- 2025** University of Pavia May 16<sup>th</sup> 2025- PhD Program in Genetics, Molecular, and Cellular Biology  
Course of Human Health and Disease.  
Pioneering strategies in disease modeling and therapeutic  
"Novel approaches in obesity therapy"
- 2024** International Consortium on Pediatric Adrenocortical Tumor (ICPACT) 1st Symposium on pediatric adrenocortical tumors November 7-8, 2024, São Paulo, Brazil
- 26/10/2022** Italian Society of Obesity  
Webinar: The Adipose Niche"
- 2022** 5° CONGRESSO NAZIONALE CLUB SIE - Endocrinologia Oncologica", Siracuse 30 June-2 July  
"Symposium: Tumori maligni del surrene" - Novel diagnostic biomarkers
- 2022** COST "HARMONIZATION" Master Classes Online meeting: March 23rd – 25th 2022  
Adrenal tumor masterclass - Basic  
Meet the expert: "Organoids in adrenal tumor research"
- 2021** Deep BiotechTalk Webinar (FRESCI.com) September 20<sup>th</sup> 2021  
"In vitro 3D Adrenal Models compared to in vivo Xenograft Models for the Study of Adrenal Tumors"
- 2021** 23rd European eCongress of Endocrinology-22 May – 26 May 2021, Prague, Czech Republic  
'How to Make an Adrenal' symposium- virtual meeting  
"3D Adrenal models for the study of adrenal tumors"
- 2020** 22nd European Congress of Endocrinology-23 May – 26 May 2020, Prague, Czech Republic  
'How to Make an Adrenal' symposium- Postponed to 2021 for COVID-19 emergency  
"Adrenal-3D"
- 2019** 1st Congress of SIRTEPS, Rome 21st June 2019 New mechanistic insights into the development and treatment of cardiovascular diseases

"Novel potential cardiac targets for anti-diabetic drugs: the SGLT2 inhibitors' story"

- 2019 SIBIOC (Italian Society of Clinical Biochemistry) Firenze, 16 aprile 2019  
La "biopsia liquida" come fonte di potenziali biomarcatori nella gestione e monitoraggio del paziente oncologico,  
"Studio delle CTC in pazienti con ACC"
- 2018 Semmelweis University, Budapest, HU, 9 May 2019 PhD Course "Genetics and genomics of endocrine tumors"  
"Studies on circulating tumor cells"
- 2017 Brunel University, London, UK, 12 April 2018  
"The multifaceted plasticity of the adipose organ"
- 2017 6<sup>th</sup> International Adrenal Cancer Symposium Sao Paulo, Brazil, 12-13 October 2017  
"New Insights in Adrenal Tumourigenesis"
- 2017 Second EASD Incretin Study Group Meeting Pisa (Italy), January 12-14 , 2017  
"Is cleaved glucagon-like peptide 1 really inactive? GLP-1(9-36) in vitro activity in human adipose stem cells"
- 2016 UNISTEM DAY Università di Firenze, 11.03.2016-European Interlab day on Stem Cells  
"La cellula Staminale Adiposa"
- 2016 University of Warwick, UK, 24 november 2016  
"Human adipose stem cells from white and brown depots:in vitro models for studying dysmetabolisms, adipogenesis and cancer"
- 2015 National Meeting Nutrizione, Obesità e Cancro, Padova 10.10.15  
"Transdifferenziazione bianco-bruno nell'ambiente peritumorale"
- 2015 National Meeting 38° Congress of the Italian Society of Endocrinology, Taormina-Italy  
"Carcinoma corticosurrenale: nuovi potenziali markers diagnostici"
- 2014 Technische Universität Dresden, GE "The adipose organ: pathophysiology and molecular biology"
- 2014 Helmholtz Zentrum München, German Research Center for Environmental Health Institute for Diabetes and Cancer-Germany- 8 September  
"Human adipose stem cell models from white and brown depots as in vitro models for studying dysmetabolism and adipogenesis"
- 2013 Regione Toscana-Università degli Studi di Firenze, S. Apollonia 24.10.2013 relatore  
"Progetti europei di ricerca & innovazione: metodi di valutazione e criteri di successo"
- 2013 University of Barcellona, Spain  
"Pheochromocytoma as a source of novel stem cell populations from ectopic brown adipose tissue in the adult"
- 2013 Technische Universität Dresden, Germany  
"Human adipose stem cell models from white and brown depots for studying dysmetabolism and adipogenesis"
- 2010 International Symposium on Adrenal Tumors, Turin, Italy  
"Preliminary studies on mitotane mechanism of action in in vitro and in vivo models of ACC"
- 2009 International Symposium on Adrenal Tumors, Padua, Italy  
"Anti-cancer effects of TZD in human adrenocortical carcinoma: from in vitro to animal studies"
- 2009 Rapid Responses to Steroid Hormones 6th International Meeting, Elche, Spain  
"Peroxisome proliferator-activated receptor-gamma (PPAR): is the genomic activity the only answer?"
- 2005 National Inter-society Meeting S.I.A.-S.I.A.Ms, Rome-Italy  
"Xenoestrogens, prenatal development and fertility"
- 2004 American Society of Andrology 30th Annual Meeting, Seattle, US  
"Nongenomic Steroid Receptors on Sperm – Signaling and Function"

- 2004 Workshop on Reproduction, Bagnoles de l'Orne, France  
"Rapid responses to estrogens"
- 2003 3rd European Congress of Andrology, Münster, Germany.  
"Enhancement of sperm motility in vitro"
- 2003 International Symposium on the Environment and Hormones, New Orleans, USA.  
"Effects of estrogens and estrogen-like compounds on differentiation of human male genitalia"
- 2002 3rd International Meeting on Rapid Effects of Steroid Hormones, University of Florence  
"Membrane effects of steroids on sperm"
- 2002 Argentinian Andrology Society & Argentinian Biology Society, Buenos Aires, Argentina  
"Molecular basis of sperm motility: in vitro treatment of asthenospermia for clinical application"
- 2002 III Mini Workshop International sobre Transduccion de Senales aplicado a la Reaccion Acrosomal y Capacitacion Espermatica, ihem, CONICET Mendoza, Argentina  
"PI3K regulation of PKA and AKAP during sperm capacitation is necessary for sperm motility".  
"Estrogens interferes with progesterone induced acrosome reaction through a novel membrane receptor"
- 2002 9th International Symposium on Spermatology, Cape Town, South Africa  
"Swimming with spermatozoa: the molecular bases of sperm motility"
- 2001 The Assisted Conception Unit, Birmingham Women's Hospital, Birmingham, UK.  
"Do human spermatozoa depend on PI3K to swim?"
- 2001 1st Virtual International Meeting in Endocrinology, www.endocrinology.org.br  
"Understanding estrogen receptor: mechanisms of signal transduction and clinical implication in male reproduction"
- 1999 British Society of Andrology, London, UK  
"Sperm interaction with Epithelia and their products"

#### SCIENTIFIC SOCIETIES

- 2022- European Association for Cancer Research (EACR)
- 2019- Top Italian Scientists Top Italian Hi su TIS
- 2018- Società Italiana di Ricerca Traslazionale e Professioni Sanitarie (SIRTEPS): Founder Member
- 2017- European Reference Network on Rare Endocrine Condition ENDO-ERN
- 2016- Società Italiana Diabete (SID)
- 2013- European Association for the Study of Diabetes (EASD)
- 2009- European Society of Endocrinology (ESE)
- 2008- European Network for the Study on Adrenal Tumors (ENSAT)
- 2012- Società Italiana Obesità (SIO)
- 2005- Società Italiana di Endocrinologia (SIE)
- 2016- Club Surrene (SIE)
- 2018- Club Endo-metabolic rare diseases (SIE)
- 2018- Club EndoOnco – Oncologic Endocrinology (SIE)

#### REVIEWER ACTIVITY

- Reviewer of international and national Research Grants** in UK, Netherlands, France, Hungary, Italy.
- Reviewer for international journals** in the field of Stem Cells, Metabolism, Endocrinology and Reproduction:

*Andrology, Asian Journal of Andrology, Biochemical Journal, Biochimical Biophysica Acta, Biochimie, Biology of Reproduction, Cancer Letters, Cell Biology International, Cells, Diabetes, Endocrine-related cancer, Endocrinology, FASEB Journal, Frontiers in Bioscience-Landmark, Frontiers in Endocrinology/oncology, Hormones and Cancer, Human Reproduction, International Journal of Andrology, International Journal of Endocrinology, International Journal of Cancer, Journal of Andrology, Journal of Cardiovascular Pharmacology, Journal of Clinical Endocrinology and Metabolism, Journal of Endocrinological Investigation, Journal of Endocrinology, Journal of Molecular Medicine, Journal of Nephrology, Journal of Sexual Medicine, Journal of Steroid Biochemistry and Molecular Biology, Journal of Urology, Molecular and Cellular Endocrinology, Molecular Human Reproduction, Molecular Reproduction and Development, Oncotarget, PlosOne, Regulatory Toxicology and Pharmacology, Reproduction, Steroids, Stem Cells, Theriogenology*

## PERSONAL SKILLS

Languages			
Mother tongue	Italian		
Other languages	UNDERSTANDING	SPEAKING	WRITING
	Listening	Reading	Spoken interaction Spoken production
English	C1	C1	C1
French	A1	A1	A1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user  
[Common European Framework of Reference for Languages](#)

<b>Organisational / managerial skills</b>	Director of Research Laboratory - Dept. Experimental & Clinical Biomedical Sciences: 3 senior post-doc, 2 studenti PhD, 4 graduating students/y  Coordinator of Division Dept. Experimental & Clinical Biomedical Sciences -UNIFI
<b>Communication skills</b>	Excellent communication skills gained through the experiences in project management, plenaries, memberships and institutional roles
<b>Computer skill</b>	Good knowledge of the main statistical programs (SPSS, Excell, Origin); Graphic and image analysis (Photoshop, Image J); writing (Word, Adobe Acrobat) Good knowledge Search engines & Databases PubMed, Scival, Web of Science, Scopus

## FUNDED RESEARCH PROJECTS

### COORDINATOR or PI

- 2025 Università di Firenze: ex 60% "Local GlucOcOrticoID hormones modulate Tumour Immune MicroenvironmEnt: the adrenocortical cancer paradigm"** (1547 euros) **PI**
- 2024 Università di Firenze: ex 60% "Targeted NGS Molecular Profiling and Its Clinical Application in Adrenocortical Cancer"** (1531 euros) **PI**
- 2023 Università di Firenze: ex 60% "Ruolo del microambiente adiposo nello sviluppo e progressione del carcinoma corticosurrenale"** (1458 euros) **PI**
- 2023 PRIN2022 Next Gen EU: Progetti Ricerca Rilevante Interesse Nazionale –Ministry of University and Research MUR-20222KAYY5 - "Integrating cutting-edge tools for targeted approach to patients with adrenocortical tumors (COOL-REACT)"** - 70.469 € **PI**
- 2023 BIOCHARME Regione Toscana FSE+ 2021-2027 (FSE+) Transizione Verde assegno di ricerca biennale Giovanisi "Nutraceutical use of vegetable bio-char in metabolic diseases BIOCHARM" – 50.000 € **PI****
- 2022 Bando Infrastructure of Research University of Florence-IR@UNIFI: "Piattaforma per la analisi SpAziaLemUltiomica in siTu single-cEll applicata alle patologie infiammatorie ed oncologiche-SALUTE"; dr 659/2023-392.000 € coordinator Andrea Galli-DSBSC-coPI**
- 2023 PNRR Tuscany Health Ecosystem THE-Spoke 3-Advanced Technologies, Methods and Materials for Human Health and Well-being- "Novel approaches for delivery of green bioactive molecules" UNIFI 270.000 €; coPI**
- 2022-2024 1 PhD Fellowship Green PON "Ricerca e Innovazione" 2014-2020 / FSE REACT-EU per il XXXVII ciclo (DM1061/2021) "100% green products to modulate the use of conventional anti-tumor drugs" (69.000 euros) PI-Dr.ssa Laura Fei**
- 2022 Università di Firenze: ex 60% "Ruolo del microambiente adiposo nello sviluppo e progressione del carcinoma corticosurrenale"** (1458 euros) **PI**

- 2020 COST ACTION CA20122 "Harmonizing clinical care and research on adrenal tumors in European countries"- HARMONISATION, Coordinator Prof D. Kastelan, University of Zagreb 5 ys (130.000 euros/y) PI**
- 2021 Università di Firenze: ex 60% "Role of carbonic anhydrase in adipose microenvironment of the adrenocortical carcinoma" (1490 euros) PI**
- 2018- Bando Ricerca Salute 2018- Ministero dell'istruzione, dell'università e della ricerca (MIUR) "EFFECTS OF MONOACYLGLYCEROLS IN COLORECTAL CANCER" acronimo MAGIC -(561.500 euros)- Cordinatore Prof. Andrea Galli- Unit PI**
- 2020 Università di Firenze: ex 60% "COCOA ASSUMPTION IN OBESITY PREVENTION AND CURE: THE ROLE OF THEOBROMINE" (1577 euros) PI**
- 2018-2019 Fondazione Ente Cassa di Risparmio di Firenze: Research Grant 2018-RF-2018.1012: "GLI ACIDI GRASSI A CATENA CORTA (AGCC) COME NUOVO APPROACCIO PREVENTIVO E TERAPEUTICO NUTRACEUTICO PER LA LIPODISTROFIA" "SHORT-CHAIN FATTY ACIDS (SCFA) AS A NOVEL NUTRACEUTIC APPROACH IN THE PREVENTION AND THERAPY OF LIPODYSTROPHY" Acronimo: AGCC-LIPO"-(10.000 euros) PI**
- 2019 Università di Firenze: ex 60% "Effect of the adipose microenvironment on cancer cell progression in adrenocortical carcinoma" (1802 euros) – PI**
- 2018-2019 Progetti competitivi per Ricercatori e Professori Associati appartenenti al Dipartimento di Scienze Biomediche Sperimentali e Cliniche nell'ambito del Progetto di Eccellenza sulla Medicina di Genere 2018-2019 A HUMAN FETAL ADRENAL CELL 3D MODEL AS A NOVEL APPROACH TO STUDY THE IMPACT OF GENETIC ALTERATIONS IN CONGENITAL ADRENAL HYPERPLASIA" - MAGICAH3D" (40.000 euros) PI**
- 2018 Università di Firenze: ex 60% "DEVELOPMENT OF A NOVEL IN VITRO MODEL OF HUMAN FETAL ADRENAL" - (1000 euros) PI**
- 2017-2018 Fondazione Ente Cassa di Risparmio di Firenze: Research Grant 2016-RF-2016.0773: "LE CELLULE STAMINALI ADIPOSE BRUNE COME NUOVO APPROACCIO TERAPEUTICO NEL DIABETE ED OBESITA"-(18.000 euros) PI**
- 2016-2018 PRIN: Progetti di Ricerca di Rilevante Interesse Nazionale – 2015ZTT5KB - PRIN 2015 Bando 2015 "DEFECTIVE TISSUE REPAIR IN METABOLIC DISORDERS: UNTANGLING ITS ROLE AND KEY MECHANISMS FOR NOVEL THERAPEUTIC APPROACHES"-(46.562 euros)-Coordinator Prof. A. Isidori -Unit PI**
- 2016 AIRC-CRF Multi-user Equipment Program 2016 Grant number 19515 "ASSAYING TUMOR METABOLIC DEREGULATION IN LIVE CELLS" – (630.000 euros)-Cordinatore Prof. P. Chiarugi-Unit PI**
- 2017 Università di Firenze: ex 60% "METABOLIC REPROGRAMMING IN ADRENOCORTICAL CARCINOMA (ACC): SEARCHING MASTER REGULATORS AS POTENTIAL TARGETS FOR INNOVATIVE THERAPIES" - (1000 euros) PI**
- 2016-2018 AIRC Investigator Grant AIRC 2015- IG2015 Id17691 3 year granted project: "DIFFERENTIAL GENOME PROFILING BETWEEN CIRCULATING AND PRIMARY TUMOR CELLS IN METASTATIC ADRENOCORTICAL CARCINOMA" - (245.000 euro) PI**
- 2016 Università di Firenze: ex 60% "STEM CELL FATE DECISIONS IN A TUMOR MICROENVIRONMENT: A POTENTIAL ROLE FOR P107" – (6.000 euros) PI**
- 2015 Università di Firenze: ex 60% "THE ROLE OF BONE MORPHOGENIC PROTEIN 7 (BMP7) IN TUMOR CROSS-TALK WITH ADIPOSE MICROENVIRONMENT IN PHEOCHROMOCYTOMA" - (2.600 euros) PI**
- 2014 Università di Firenze: ex 60% "EFFETTI DI UN FARMACO UTILIZZATO NELLA TERAPIA DEL DIABETE DI TIPO 2, METFORMINA, SUL CARCINOMA CORTICOSURRENALICO" - PI**
- 2014-2015 Fondazione Ente Cassa di Risparmio di Firenze 2014: CARATTERIZZAZIONE BIOLOGICA E MOLECOLARE DEL TUMORE POLMONARE AVANZATO: ANALISI**

**PARALLELA NELL'AGO ASPIRATO DEL TUMORE PRIMITIVO E NELLE CELLULE TUMORALI CIRCOLANTI –Cordinatore Prof. M. Pazzaglia-Unit PI**

- **2013** Università di Firenze: ex 60% “CARATTERIZZAZIONE DI CELLULE STAMINALI DI TESSUTO ADIPOSO BRUNO UMANO” - **PI**
- **2012** Università di Firenze: ex 60% “IDENTIFICAZIONE DI BIOMARCATORI DIAGNOSTICI E PROGNOSTICI DEL TUMORE ADRENOCORTICALE A LIVELLO TISSUTALE ED EMATICO” - **PI**
- **2011** Università di Firenze: ex 60% “MODELLI IN VITRO DI CELLULE STAMINALI ADULTE UMANE DA TESSUTO ADIPOSO PER LO STUDIO DELLA DIFFERENTE RISPOSTA METABOLICO-FUNZIONALE NELLA LIPODISTROFIA” - **PI**
- **2012-2014** Novo Nordisk research grant: “EFFECTS OF LIRAGLUTIDE ON HUMAN ADIPOSE CELLS AND ADIPOSE TISSUE IN VITRO”- (84.000 euros)- **PI**
- **2009-2010** Fondazione Ente Cassa di Risparmio di Pistoia e Pescia 2009: “RUOLO DELL’INFIAMMAZIONE NELLE ALTERAZIONI DEL TESSUTO ADIPOSO CHE ESITANO NELL’OBESITÀ PATHOLOGICA”. Prot. 2009.0221- (29.000 euros)- **PI**
- **2009-2010** Fondazione Ente Cassa di Risparmio di Firenze 2009. “RUOLO DELL’INFIAMMAZIONE NELLE ALTERAZIONI DEL TESSUTO ADIPOSO ALLA BASE DELL’OBESITÀ PATHOLOGICA E DELLE MALATTIE METABOLICHE”. Prot. 2010.0547- (19.000 euros) - **PI**
- **2009** Università di Firenze: ex 60% “DIFFERENZE FUNZIONALI NELLE CELLULE ADIPOSE STAMINALI UMANE OTTENUTE DA TESSUTO ADIPOSO VISCERALE E SOTTOCUTANEO DI SOGGETTI NORMOPESO ED OBESI” - **PI**
- **2008** Università di Firenze: ex 60% “RUOLO DELL’ADIPONECTINA NELLA RISPOSTA ENDOTELIALE AL DANNO VASCOLARE” - **PI**
- **2007** Università di Firenze: ex 60% “RUOLO DEI TIAZOLIDINEDIONI NEL PROCESSO INFAMMATORIO VASCOLARE” - **PI**
- **2006-2008** Call for Rare Diseases UNIVERSITA’ LA SAPIENZA di ROMA. THE BLADDER EXTROPHY-EPISPADIAS COMPLEX AND EXOGENOUS RISK FACTORS (**BLADE**). Coordinator Prof. Mantovani ISS-**Unit PI**
- **2006** Università di Firenze: ex 60% “CARATTERIZZAZIONE DELLA CASCATA DI SEGNALAZIONE DELLA PROTEIN CHINASI A (PKA) NEGLI SPERMATOZOI UMANI” – **PI**
- **2005** Università di Firenze: ex 60% “CARATTERIZZAZIONE DEL RECETTORE NONGENOMICO DEL PROGESTERONE IN SPERMATOZOI UMANI” – **PI**

#### COLLABORATOR

- **2025-2027** EU4H-2024-PJ-03 Support of Personalized medicine Approaches in Cancer- SPARC- Coordinator Manuel Ottaviano, Universidad Politecnica de Madrid (3 million euros).
- **2023-2027** Dept. of Excellence Italian Program 2023-2027 Project “La medicina di genere: dal “single cell” alla clinica”-“Gender Medicine: from single cell to the clinics”-PI Andrea Galli, Head of the Dept. Experimental and Clinical Biomedical Sciences (9 millions euros).
- **2020** ESE European Research Support Grant (SEEDER EU) Project: Harmonizing clinical care and improve research on adrenal tumors in Europe Lead: Martin Fassnacht, University Hospital Würzburg (15.000 euros)
- **2015-2019** Liberal Fund non profit PARADIFFERENCE: “THE ROLES OF MICROENVIRONMENT AND MITOCHONDRIA SUCCINATE DEHYDROGENASE IN PARAGANGLIOMA DEVELOPMENT AND PROGRESSION”. PI Prof. M.Mannelli’s Unit. (527.000 euros)

- 2014-2015** Fondazione Ente Cassa di Risparmio di Firenze 2014: "EFFETTO DELL'OBESITA' E DELLA PERDITA DI PESO SULLO STATO DI METILAZIONE DEL GAMETE MASCHILE: EFFETTI METABOLICI E EREDITARIETA' PATERNA". PI Prof. G. Forti (20.000 euros)
- 2013-2014** Fondazione Ente Cassa di Risparmio di Firenze 2013: "RUOLO DEGLI ORMONI ANDROGENI NELLA DISFUNZIONE METABOLICA DEL TESSUTO ADIPOSO DEL MASCHIO OBESO (ANDROMOB)". PI Prof. G. Forti (25.000 euros)
- 2011-2015-** PRIN 2010: "AMLET-ANDROGENI, METABOLISMO, STILE DI VITA, AMBIENTE: FUNZIONE TESTICOLARE PER LA SALUTE"-protocollo 2010C8ERKX in G. Forti's Unit 7 (104.000 euros), Coordinatore Manuela Simoni (Università degli Studi di Modena).
- 2011-2016- FP7 Cooperation:** "ENS@T-Cancer-EUROPEAN NETWORK FOR THE STUDY OF ADRENAL TUMOURS-STRUCTURING CLINICAL RESEARCH ON ADRENAL CANCERS IN ADULTS" Progetto Cooperation Seventh Framework Programme (FP7/2007-2013) grant agreement n° 259735, in Massimo Mannelli's Unit (50.000 euros), Coordinatore Prof. Felix Beuschlein (University of Munich, GE).
- 2011-2015- FIRB2010:** "STUDY OF MOLECULAR MARKERS FOR DIAGNOSIS AND PROGNOSIS AND DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR ADRENOCORTICAL CANCER" (prot number: RBAP1153LS) in Massimo Mannelli's Unit (106.000 euros), Coordinatore Prof. Franco Mantero (Università degli Studi di Padova)
- 2010-2012 REGIONE TOSCANA,** Programma per la Ricerca Regionale in Materia di Salute 2009 "DEVELOPMENT OF NEW DIAGNOSTIC METHODS FOR THE GENETIC ASSESSMENT OF INFERTILE MALES AND FOR THE PREDICTION OF THE OUTCOME OF ASSISTED REPRODUCTIVE TECHNIQUES IN COUPLES WITH 'MALE FACTOR' INFERTILITY", Coordinatore Prof. G. Forti.
- 2008-2010 ISTITUTO TOSCANO TUMORI-ITT2007:** "THE PROTEOMIC APPROACH FOR IDENTIFICATION OF PUTATIVE BIOMARKERS AND CHARACTERIZATION OF THE MOLECULAR BASES OF HUMAN ADRENOCORTICAL CANCER", PI Prof. M. Mannelli prot number: AOOGRT/Q.80.110
- 2008-2009** Fondazione Ente Cassa di Risparmio di Firenze 2007 "TUMORE DELLA SURRENE: RUOLO DEGLI ESTROGENI E ANALISI PROTEOMICA", Coordinatore Prof. M. Mannelli.
- 2000-2002** World Health Organization 2000 prot. IDA05022 "CHARACTERIZACIÓN DE LAS MEMBRANAS NO GENÓMICAS DE LOS RECEPTORES DE PROGESTERONA EN SPERMATOZOIDES", Prof. G. Forti PI.

## INTERNATIONAL PEER-REVIEWED JOURNALS

\* Correspondence

Year		IF at pub	IF 2020	Citations Scopus
1994 1	1. Baldi E., Bonaccorsi L., Finetti G., <b>Luconi M.</b> , Muratori M., Susini T., Forti G., Serio M. and Maggi M. Platelet-activating factor in human endometrium. <i>J. Steroid Biochem. Molec. Biol.</i> 1994;49: 359-363.	1.709	4.292	19
1995 4	1. <b>Luconi M.</b> , Bonaccorsi L., Krausz Cs., Gervasi G., Forti G. and Baldi E. Stimulation of protein tyrosine phosphorylation by platelet-activating factor and progesterone in human spermatozoa. <i>Mol Cell Endocrinol.</i> 1995;108: 35-42. 2. Krausz Cs., Bonaccorsi L., <b>Luconi M.</b> , Fuzzi B., Criscuoli L., Pellegrini S., Forti G. and Baldi E. Intracellular calcium increase and acrosome reaction in response to progesterone in human spermatozoa correlates with in vitro fertilization. <i>Hum. Reprod.</i> 1995;10: 120-124. 3. Bonaccorsi L., <b>Luconi M.</b> , Forti G. and Baldi E. Tyrosine kinase inhibition reduces the plateau phase of the calcium increase in response to progesterone in human sperm. <i>FEBS Letters</i> 1995;364: 83-86. 4. Baldi E., Krausz Cs., <b>Luconi M.</b> , Bonaccorsi L., Maggi M. and Forti G. Actions of progesterone on human sperm: a model of non-genomic effects of steroids. <i>J. Steroid Biochem. Molec. Biol.</i> 1995;53: 199-203.	2.064 2.421 3.504 1.709	4.102 6.918 4.124 4.292	95 81 72 35
1996 5	1. Giannini S., M. Maggi, B. Cresci, G. Finetti, L. Bonaccorsi, <b>M. Luconi</b> , C. M. Rotella, G. Forti, M. Serio and E. Baldi. Platelet-activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line (Hec-1A). <i>Gynecol. Oncol.</i> 1996;61: 333-340. 2. <b>Luconi M.</b> , Cs. Krausz, G. Forti and E. Baldi. Extracellular calcium negatively modulates tyrosine phosphorylation and tyrosine kinase activity during capacitation of human spermatozoa. <i>Biol. Reprod.</i> 1996;55: 207-216. 3. Baldi E., <b>M. Luconi</b> , L. Bonaccorsi, Cs. Krausz and G. Forti. Human sperm activation during capacitation and acrosome reaction: role of calcium, protein phosphorylation and lipid remodelling pathways. <i>Frontiers Biosci-Lenadmark</i> 1996;1:d189-205, (invited review). 4. <b>Luconi M*</b> . Report of the 9th European Workshop on Molecular and Cellular Endocrinology of the Testis. <i>Int. J. Androl.</i> 1996; 19:129-134. 5. Krausz Cs., L. Bonaccorsi, P. Maggio, <b>M. Luconi</b> , L. Criscuoli, B. Fuzzi, S. Pellegrini, G. Forti and E. Baldi. Two functional assays of sperm responsiveness to progesterone and their predictive values in in-vitro fertilization. <i>Hum Reprod.</i> 1996;11: 1661-1667.	1.542 3.036 3.063 0.984 2.421	5.482 4.285 4.009 3.695 6.918	8 148 69 0 88
1997 2	1. Bonaccorsi L., <b>M. Luconi</b> , M. Maggi, M. Muratori, G. Forti, M. Serio and E. Baldi. Protein tyrosine kinase, mitogen-activated protein kinase and protein kinase C are involved in the mitogenic signaling of platelet-activating factor (PAF) in HEC-1A cell. <i>Biochimica et Biophysica Acta-Molecular Cell Research</i> 1997;1355:155-166. 2. Muratori M., I. Nicoletti, G.B. Vannelli, <b>M. Luconi</b> , E. Maccorsini, M. Serio, G. Forti and M. Maggi. Genistein induces G2/M block and apoptosis in human endometrial cancer cell lines. <i>Endocrine-Related Cancer</i> 1997;4: 203-218.	3.171 0.983	4.739 5.678	23 2

1998 5	<p>1. <b>Luconi M.</b>, Krausz C., Barni T., Vannelli G.B., Forti G. and Baldi E. Progesterone stimulates p42 extracellular-signal regulated kinase (p42<sup>ERK</sup>) in human spermatozoa. <i>Mol. Hum Reprod.</i> 1998;4: 251-258.</p> <p>2. <b>Luconi M.</b>, Bonaccorsi L., Maggi M., Pecchioli P., Krausz Cs., Forti G. and Baldi E. Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. <i>J Clin Endocrin Metab.</i> 1998;83: 877-890.</p> <p>3. <b>Luconi M.</b>, T. Barni, G. B. Vannelli, Cs. Krausz, F. Marra, P. A. Benedetti, V. Evangelista, G. Forti and E. Baldi. Extracellular-signal regulated kinases (ERKs) modulate capacitation of human spermatozoa. <i>Biol. Reprod.</i> 1998;58:1476-1489.</p> <p>4. Baldi E., <b>Luconi M.</b>, L. Bonaccorsi, G. Forti. Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. <i>Frontiers Biosci-Landmark</i> 1998;3:d1051-1059 (invited review).</p> <p>5. Baldi E., <b>Luconi M.</b>, Bonaccorsi L., Forti G. Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implication. <i>Pediatric Pathology and Molecular Medicine</i>, 1998-1999; 18:417-431. Review no IF no PubMed</p>	3.643  5.641  3.327  3.063  -	4.025  5.958  4.285  4.009  -	78  146  138  57  2
1999 6	<p>1. Baldi E., <b>Luconi M.</b>, L. Bonaccorsi, M. Maggi, S. Francavilla, A. Gabriele, G. Properzi, G. Forti. Nongenomic progesterone receptor on human spermatozoa: biochemical aspects and clinical implications. <i>Steroids</i> 1999;64:143-148.</p> <p>2. <b>Luconi M*</b>, M. Muratori, G. Forti and E. Baldi. Identification and characterization of a novel functional estrogen receptor on human sperm membrane which interferes with progesterone effects. <i>J. Clin. Endocrin. Metab.</i> 1999;84: 1670-1678.</p> <p>3. Forti G., Baldi E., Krausz Cs., <b>Luconi M.</b>, Bonaccorsi L., Maggi M., Bassi F., Scarselli G. Les effects de la progesterone sur le spermatozoide humain: implications cliniques. <i>Ann. Endocrinol.</i> 1999 ;60:107-110.</p> <p>4. Romagnani P., Beltrame C., Annunziato F., Lasagni L., <b>Luconi M.</b>, Galli G., Cosmi L., Maggi E., Salvadori M., Pupilli C and Serio M. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. <i>J. Am. Soc. Nephrol.</i> 1999;10: 2518-2526.</p> <p>5. Barni T., Maggi M., Fantoni G., Granchi S., Mancina R., Gulisano M., Marra F., Maccorsini E., <b>Luconi M.</b>, Rotella C., Serio M., Balboni G.C., Vannelli G.B. Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. <i>J. Clin. Endocrinol. Metab.</i> 1999;84: 4266-4273.</p> <p>6. Baldi E., <b>Luconi M.</b>, Bonaccorsi L., Forti G. Nongenomic effects of progesterone on spermatozoa: relevance to sperm function. <i>Current Topics in Steroid Research</i>, 1999; 2:119-125. review no IF no PubMed</p>	2.583  5.805  0.405  6.182  5.805  -	2.668  5.958  2.478  10.121  5.958  -	45  160  10  112  41  0
2000 8	<p>1. El-Hefnawy T., PR. Manna, <b>M. Luconi</b>, E. Baldi, J. P. Slotte and I. Huhtaniemi. Progesterone action in a murine Leydig Tumor Cell Line (mLTC-1) possibly through a non-classical receptor type. <i>Endocrinol.</i> 2000;141: 247-255.</p> <p>2. <b>Luconi M.</b>, Bonaccorsi L., Forti G., Baldi E. Signal transduction mechanisms in human spermatozoa: from physiology to possible new therapeutic applications. <i>Emerging Therapeutic Targets</i> 2000;4: 239-253,. review no IF no PubMed</p> <p>3. Maggi M., Barni T., Fantoni G., Mancina R., Pupilli C., <b>Luconi M.</b>, Crescioli C., Serio M., Vannelli G.B. Expression and biological effects of endothelin-1 in human gonadotropin-releasing hormone-secreting neurons. <i>J. Clin. Endocrinol. Metab.</i> 85:1658-1665, 2000.</p> <p>4. Baldi E., <b>Luconi M.</b>, Muratori M., Forti G. A novel functional estrogen receptor on human sperm membrane interferes with progesterone effects. <i>Mol. Cell. Endocrinol.</i> 2000;161: 31-35.</p> <p>5. Crescioli C., Maggi M., Vannelli G.B., <b>Luconi M.</b>, Salerno R., Barni T., Gulisano M., Forti G., Serio M. Effects of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. <i>J. Clin. Endocrinol. Metab.</i> 2000;85: 2576-2583</p> <p>6. <b>Luconi M.</b>, M. Muratori, M. Maggi, P. Pecchioli, A. Peri, M. Mancini, E. Filimberti, G. Forti. and E. Baldi. Uteroglobin (UG) and transglutaminase (TG) modulate human sperm functions. <i>J. Androl.</i>2000;21: 676-688.</p> <p>7. Baldi E., <b>M. Luconi</b>, L. Bonaccorsi, M. Muratori and G. Forti. Intracellular events and signaling pathways involved in sperm acquisition of fertilizing</p>	4.790  -  5.447  2.369  5.447  2.106  3.063	4.736  -  5.958  4.102  5.958  3.69  4.009	45  0  15  55  39  12  100

	capacity and acrosome reaction. <i>Frontiers in Biosci-Landmark</i> 2000;5: d880-893. 8. Peri A., Bonaccorsi L., Muratori M., <b>Luconi M.</b> , Baldi E., Granchi S., Pesciullesi A., Mini E., Cioppi F., Forti G., Serio M., Miele L., Maggi M. Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. <i>Int. J. Cancer.</i> 2000;88, 525-534.	3.918	7.396	18
2001 2	1. <b>Luconi M.</b> , Bonaccorsi L., Forti G., Baldi E. Effects of estrogenic compounds on human spermatozoa: evidence for interaction with a nongenomic receptor for estrogen on human sperm membrane. <i>Mol. Cell. Endocrinol</i> 2001;178:39-45. 2. <b>Luconi M.</b> , Marra F., Gandini L., Lenzi A., Filimberti E., Forti G., Baldi E. Phosphatidylinositol 3-kinase inhibition enhances human sperm motility. <i>Hum. Reprod.</i> 2001;16:1931-1937.	2.405	4.102	57
		2.987	6.918	50
2002 8	1. Baldi E., <b>Luconi M.</b> , Bonaccorsi L., Forti G. Signal Transduction pathways in human spermatozoa. <i>J Reprod Immunol.</i> 2002;53:121-31. 2. Crescioli C., Maggi M., <b>Luconi M.</b> , Vannelli G. B., Salerno R., Sinisi A.A., Bonaccorsi L., Ferruzzi P., Barni T., Forti G., Serio M. Vitamin D <sub>3</sub> analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. <i>Prostate</i> 2002;50:15-26. 3. <b>Luconi M.</b> , Bonaccorsi L., Bini L., Liberatori S., Pallini V., Forti G., Baldi E. Characterization of membrane nongenomic receptors for progesterone in human spermatozoa. <i>Steroids</i> 67:505-509, 2002. 4. <b>Luconi M*</b> , Forti G., Baldi E. Genomic and nongenomic effects of estrogens: molecular mechanisms of action and clinical implications for male reproduction. <i>J. Steroid Biochem. Mol. Biol.</i> 2002;80:1-13. 5. Filippi S., <b>Luconi M.</b> , Granchi S., Natali A., Forti G., Ledda F., Maggi M. Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. <i>Int. J. Impot. Res.</i> 2002;14:295-307. 6. Filippi S., Vannelli G.B., Granchi S., <b>Luconi M.</b> , Crescioli C., Mancina R., Natali A., Brocchi S., Vignozzi L., Bencini E., Noci I., Ledda F., Forti G., Maggi M. Identification, localization and functional activity of oxytocin receptors in epididymis. <i>Mol. Cell. Endocrinol.</i> 2002;193:89-100. 7. Filippi S., <b>Luconi M.</b> , Granchi S., Vignozzi L., Bettuzzi S., Tozzi P., Ledda F., Forti G., Maggi M. Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. <i>Endocrinol.</i> 2002;143: 4271-4280. 8. Granchi S., Vannelli G.B., Vignozzi L., Crescioli C., Ferruzzi P., Mancina R., Vinci M.C., Forti G., Filippi S., <b>Luconi M.</b> , Ledda F., Maggi M. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. <i>Mol. Hum. Reprod.</i> , 2002;8:1053-1064.	2.361 3.151 2.524 2.637 2.539 2.698 5.095 2.968	4.054 4.104 2.668 4.292 1.681 4.102 4.736 4.025	77 43 44 104 36 64 62 74
2003 4	1. Crescioli C., Maggi M., Vannelli G.B., Ferruzzi P., Granchi S., Mancina R., Muratori M., Forti G., Serio M., <b>Luconi M*</b> . Expression of functional estrogen receptors in human fetal male external genitalia. <i>J. Clin. Endocrinol. Metab.</i> , 2003;88:1815-1824. 2. <b>Luconi M*</b> . and Baldi E. How do sperm swim?: molecular mechanisms underlying sperm motility. <i>Cell Mol Biol.</i> 2003;49: 357-369. 3. Filippi S., M. Marini, G.B. Vannelli, C. Crescioli, S. Granchi, L. Vignozzi, <b>M. Luconi</b> , P. Ferruzzi, A. Morelli, G. Forti, F. Ledda and M. Maggi. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. <i>Mol. Hum Reprod.</i> , 2003, 9:765-774. 4. Peri A., Bonaccorsi L., Cioppi F., Muratori M., <b>Luconi M.</b> , Granchi S., Maggi M., Baldi E. The effects of an autocrine loop mediated by platelet-activating factor (PAF) in HEC-1A cells are reverted by uteroglobin. <i>Hum Cell</i> 2003;16:95-9.	5.873 1.153 3.067 1.129	5.958 1.372 4.025 3.463	57 27 40 1
2004 8	1. Du Plessis S.S., Franken D.R., Baldi E., <b>Luconi M.</b> Phosphatidylinositol 3-kinase inhibition enhances human. <i>Int. J. Androl.</i> , 2004;27:19-26. 2. Romanelli R.G., Barni T., Maggi M., <b>Luconi M.</b> , Failli P., Pezzatini A., Pelo E., Torricelli F., Crescioli C., Ferruzzi P., Salerno R., Marini M., Rotella C.M., and Vannelli G.B. Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. <i>J. Biol. Chem.</i> 2004;279:117-126.	1.941 6.355	3.695 5.157	20 46

	<p>3. <b>Luconi M*</b>, Carloni V., Marra F., Ferruzzi P., Forti G. and Baldi E. Increased phosphorylation of AKAP by inhibition of phosphatidylinositol 3-kinase enhances human sperm motility through tail recruitment of protein kinase A. <i>J. Cell Sci.</i> 2004;117:1235-1246.</p> <p>4. Vignozzi L., Filippi S., <b>Luconi M.</b>, Morelli A., Marini M., Mancina R., Vannelli G.B., Granchi S., Orlando C., Gelmini S., Ledda F., Forti G., Maggi M. Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility. <i>Endocrinol.</i> 2004;145:1823-1834.</p> <p>5. Morelli A., Filippi S., Mancina R., <b>Luconi M.</b>, Vignozzi L., Marini M., Orlando C., Vannelli G.B., Aversa A., Natali A., Forti G., Giorgi M., Jannini E.A., Ledda F., Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. <i>Endocrinol.</i> 2004;145:2253-2263.</p> <p>6. <b>Luconi M.</b>, Francavilla F., Porazzi I., Forti G., Baldi E. Human spermatozoa as a model for studying membrane receptors mediating rapid nongenomic effects of progesterone and estrogens. <i>Steroids</i> 2004;69:553-559.</p> <p>7. Muratori M., Porazzi I., <b>Luconi M.</b>, Marchiani S., Forti G., Baldi E. AnnexinV binding and merocyanine staining fail to detect human sperm capacitation. <i>J. Androl.</i> 2004;25:797-812.</p> <p>8. Gelmini S., Poggesi M., Distante V., Bianchi S., Simi L., .., <b>Luconi M.</b>, Casini Raggi C., Cataliotti L., Pazzagli M., Orlando C. Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. <i>Cancer Lett.</i> 2004;216:81-87.</p>	6.910 5.151 5.151 2.337 2.394 2.938	5.285 4.736 4.736 2.523 3.695 8.679	81 57 285 122 68 74
2005 10	<p>1. <b>Luconi M</b> *, I. Porazzi, P. Ferruzzi, S. Marchiani, G. Forti, and E. Baldi. Tyrosine Phosphorylation of the A Kinase Anchoring Protein 3 (AKAP3) and Soluble Adenylate Cyclase Are Involved in the Increase of Human Sperm Motility by Bicarbonate. <i>Biol Reprod</i> 2005; 72: 22-32.</p> <p>2. Crescioli C, Morelli A, Adorini L, Ferruzzi P, <b>Luconi M</b>, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D, Forti G, Colli E, Andersson KE, Maggi M Human Bladder as a Novel Target for Vitamin D Receptor Ligands. <i>J Clin Endocrinol Metab</i> 2005; 90:962-972.</p> <p>3. Zhang X, Morelli A, <b>Luconi M</b>, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone Regulate PDE5 Expression and Tadalafil in vivo Responsiveness in Rat Corpus Cavernosum. <i>Eur Urol</i> 2005; 47: 409-416.</p> <p>4. Zhang X, Filippi S, Vignozzi L, Morelli A, Mancina R, <b>Luconi M</b>, Donati S, Marini M, Vannelli GB, Forti G, Maggi M. Identification, localization and functional "in vitro" and "in vivo" activity of oxytocin receptor in the rat penis. <i>J Endocrinol</i> 2005, 184:567-576.</p> <p>5. Vignozzi L, Vannelli GB, Morelli A, Mancina R, Marini M, Ferruzzi P, Crescioli C, <b>Luconi M</b>, Donati S, Fisher AD, Baldi E, Filippi S, Forti G, Maggi M. Identification, characterization and biological activity of oxytocin receptor in the developing human penis. <i>Mol Hum Reprod</i> 2005; 11:99-106.</p> <p>6. Romanelli RG., Barni T, Maggi M, <b>Luconi M</b>, Failli P, Pezzatini A, Morelli A, Maggi R, Zaninetti R, Salerno R, Ambrosini S, Marini M, Rotella C, Vannelli GB. Role of Endothelin-1 in the migration of human olfactory Gonadotropin-Releasing Hormone-secreting neuroblasts. Evidence of requirement for endothelin- receptor B signaling during development. <i>Endocrinology</i> 2005; 146: 4321-4330.</p> <p>7. <b>Luconi M*</b>, Torcia S, Grillo D, Fiorenza MT, Forti G, Mangia F, Baldi E. Enhancement of sperm motility by the PI3-kinase inhibitor ly294002 does not result in toxic effect on preimplantation embryo development in the mouse. <i>Hum Reprod.</i> 2005; 20:3500-4.</p> <p>8. Morelli A, Filippi S, Zhang X, <b>Luconi M</b>, Vignozzi L, Mancina R and Maggi M. Peripheral regulatory mechanisms in erection. <i>Int J Androl</i> 2005;Suppl 2:23-7.</p> <p>9. Brewis IA, Moore HD, Fraser LR, Holt WV, Baldi E, <b>Luconi M</b>, Gadella BM, Ford WC, Harrison RA. Molecular mechanisms during sperm capacitation. <i>Hum Fertil</i> 2005; 8:253-61.</p> <p>10. <b>Luconi M</b>. Immunolocalization of androgen receptor and estrogen receptors <math>\alpha</math> and <math>\beta</math> in human fetal testis and epididymis: Editorial comment. <i>Journal of Urology</i> 2005; 174(4 II), pp. 1698.</p>	3.583 6.020 3.542 3.059 3.191 5.313 3.669 2.306 1.377 3.592	3.184 5.789 20.096 4.012 3.499 3.961 6.918 3.695 2.767 7.450	83 82 157 34 13 9 14 45 19 2

2006 3	1. <b>Luconi M*</b> , Forti G, Baldi E. Pathophysiology of sperm motility. <i>Frontiers Biosci-Landmark</i> 2006;11:1433-1447 2. Zhang Xh, Filippi S, Morelli A, Vignozzi L, <b>Luconi M</b> , Donati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. <i>J Sex Med.</i> 2006; 3:253-66. 3. Vignozzi L, Filippi S, Morelli A, Ambrosini S, <b>Luconi M</b> , Vannelli GB, Donati S, Crescioli C, Zhang XH, Mirone V, Forti G, Maggi M. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. <i>J Sex Med.</i> 2006; 3:419-31.	2.771  4.676  4.676	4.009  3.802  3.802	48  111  110	
2007 1	1. Vignozzi L, Morelli A, Filippi S, Ambrosini S, Mancina R, <b>Luconi M</b> , Mungai S, Vannelli GB, Zhang XH, Forti G, Maggi M. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. <i>J Sex Med.</i> 2007; 4:620-30.	6.199	3.802	109	
2008 7	1. Ercolino T, Lombardi A, Becherini L, Piscitelli E, Cantini G, Gaglianò MS, Serio M, <b>Luconi M</b> , Mannelli M. The Y606C RET mutation causes a receptor gain of function. <i>Clinical Endocrinol.</i> 2008; 69:253-82. 2. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, <b>Luconi M*</b> . A new mechanism involving ERK contributes to rosiglitazone inhibition of TNF $\alpha$ and IFN $\gamma$ inflammatory effects in human endothelial cells. <i>Arterioscler Thromb Vasc Biol</i> 2008; 28:716-724. 3. Borgogni E, Sarchielli E, Sottili M, Santarasci V, Cosmi L, Gelmini S, Lombardi A, Cantini G, Perigli G, <b>Luconi M</b> , Vannelli GB, Annunziato F, Adorini L, Serio M, Crescioli C. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. <i>Endocrinology</i> 2008. 149:3626-34. 4. Morelli A, Marini M, Mancina R, <b>Luconi M</b> , Vignozzi L, Fibbi B, Filippi S, Pezzatini A, Forti G, Vannelli GB, Maggi M. Sex Steroids and Leptin Regulate the "First Kiss" (KISS1/G-Protein-Coupled Receptor 54 System) in Human Gonadotropin-Releasing-Hormone-Secreting Neuroblasts. <i>J Sex Med</i> 2008; 5:1097-113. 5. Vignozzi L, Filippi S, Morelli A, <b>Luconi M</b> , Jannini E, Forti G, Maggi M. Regulation of epididymal contactility during semen emission, the first part of the ejaculatory process: a role for estrogen. <i>J Sex Med</i> 2008; 5:2010-6. 6. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, Ercolino T, Galli A, Serio M, Mannelli M, <b>Luconi M*</b> . Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signalling. <i>PPAR Res.</i> 2008;904041. 7. Varano G, Lombardi A, Cantini G, Forti G, Baldi E, <b>Luconi M*</b> . Src activation triggers capacitation and acrosome reaction but not motility in human spermatozoa. <i>Hum Reprod.</i> 2008 23: 2652-62.	3.398  6.858  4.945  5.393  5.393  2.727  3.773	3.478  8.311  4.736  3.802  3.802  4.964  6.918	9  67  49  55  47  52	
2009 4	1. Muratori M, <b>Luconi M</b> , Marchiani S, Forti G, Baldi E. Molecular markers of human sperm functions. <i>Int J Androl</i> 2009; 32:25-42. 2. Baldi E, <b>Luconi M</b> , Muratori M, Marchiani S, Tamburino L, Forti G. Nongenomic activation of spermatozoa by steroid hormones: Facts and fictions. <i>Mol Cell Endocrinol</i> 2009; 308:39-46. 3. Baglioni S, Francalanci M, Squecco R, Lombardi A, Cantini G, Angeli R, Gelmini S, Guasti D, Benvenuti S, Annunziato F, Bani D, Liotta F, Francini F, Perigli G, Serio M, <b>Luconi M*</b> . Characterization of human adult stem cell populations isolated from visceral and subcutaneous adipose tissue. <i>FASEB J</i> 2009; 23:3494-3505. 4. Lombardi A, Cantini G, Mello T, Francalanci M, Gelmini S, Cosmi L, Santarasci V, Degl'Innocenti S, Luciani P, Deledda C, Annunziato F, Forti G, Galli A, Serio M, <b>Luconi M*</b> . Molecular mechanisms underlying the pro-inflammatory synergistic effect of TNF $\alpha$ and IFN $\gamma$ in human microvascular endothelium. <i>Eur J Cell Biol</i> 2009; 88:731-742.	3.705  3.503  6.401  3.314	3.695  4.102  5.191  4.492	30  118  148  22	
2010 4	1. <b>Luconi M*</b> , Cantini G, Serio M. Peroxisome proliferator-activated receptor-gamma (PPAR $\gamma$ ): is the genomic activity the only answer? <i>Steroids</i> 2010; 75:585-94. 2. <b>Luconi M*</b> , Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, Ercolino T, Serio M, Orlando C, Mannelli M. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical	3.106  4.432	2.668  5.678	71  25	

	study in a xenograft mouse model. <i>Endocrine-Related Cancer</i> 2010; 17:169-77 3. Cantini G, Lombardi A, Borgogni E, Francalanci M, Ceni E, Degl'Innocenti S, Gelmini S, Poli G, Galli A, Serio M, Forti G, <b>Luconi M*</b> . Peroxisome-Proliferator-Activated Receptor Gamma (PPARy) Is Required For Modulating Endothelial Inflammatory Response Through A Nongenomic Mechanism. <i>Eur J Cell Biol</i> 2010; 89:645-53 4. Mannelli M, G Cantini, G Poli, M Mangoni, G Nesi, L Canu, E Rapizzi, E Borgogni, T Ercolino, V Piccini, <b>M Luconi</b> . The role of PPAR-γ system in normal and tumoral corticotroph pituitary and adrenal cells. <i>Neuroendocrinology</i> 2010; 92:23-7.	3.630  3.272	4.492  4.914	18  14
2011 3	1. <b>Luconi M*</b> , Cantini G, Baldi E, Forti G. Role of A-Kinase Anchoring Proteins In Reproduction. Invited review. <i>Frontiers Biosci-Landmark</i> 2011; 16:1315-30 2. Muratori M, Marchiani S, Tamburino L, Forti G, <b>Luconi M</b> , Baldi E. Markers of Human Sperm Functions In The ICSI Era. Invited review. <i>Frontiers Biosci</i> 2011; 16:1344-63. 3. Baldi E, <b>Luconi M</b> , Krausz C, Forti G. Progesterone and spermatozoa: a long-lasting liaison comes to definition. <i>Hum Reprod.</i> 2011;26:2933-4.	3.488  3.488  4.475	4.009  4.009  6.918	35  16  12
2012 2	1. <b>Luconi M*</b> , Mannelli M. Xenograft models for preclinical drug testing: implications for adrenocortical cancer. <i>Mol Cell Endocrinol.</i> 2012 31;351:71-77. 2. Baglioni S, Cantini G, Poli G, Francalanci M, Squecco R, Di Franco A, Borgogni E, Frontera S, Nesi G, Liotta F, Lucchese M, Perigli G, Francini F, Forti G, Serio M, <b>Luconi M*</b> . Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. <i>PLoS One</i> 2012; 7:e36569.	4.039  3.534	4.102  2.766	17  110
2013 7	1. Facchiano E, Scaringi S, Veltri M, Samavat J, Maggi m, Forti G, <b>Luconi M</b> , Lucchese M. Age as a predictive factor of testosterone improvement in male patients after bariatric surgery: preliminary results of a monocentric prospective study. <i>Obesity Surgery</i> 2013; 23:167-72. 2. Perigli G, Qirici E, Badii B, Kokomani A, Staderini F, <b>Luconi M</b> , Crescioli C, Mannelli M, Maggi M, Cianchi F. Feasibility and safety of minimal-incision thyroidectomy for Graves' disease: A prospective, single-center study. <i>Head Neck</i> 2013; 35:1345-8 3. Liotta L, Di Franco A, Pazzaglia M, <b>Luconi M*</b> . Glycated hemoglobin (HbA1c) measurement in frozen whole blood depends on baseline values of fresh samples. <i>Anal Bioanal Chem.</i> 2013 405:429-434. 4. Corona G, Rastrelli G, Monami M, Saad F, <b>Luconi M</b> , Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a meta-analytic study. <i>Eur J Endocrinol.</i> 2013;168:829-43. 5. <b>Luconi M</b> , Samavat J, Seghieri G, Iannuzzi G, Lucchese M, Rotella C, Forti G, Maggi M, Mannucci E. Determinants of testosterone recovery after bariatric surgery: Is it only a matter of reduction of body mass index? <i>Fertil Steril.</i> 2013;99:1872-1879.e1. 6. Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandinelli A, Cini N, Bani D, Mannelli M, <b>Luconi M*</b> . Morpho-functional effects of mitotane on mitochondria in human adrenocortical cancer cells. <i>Endocrine Relat Cancer.</i> 2013;20:537-50. <b>Selected Cover</b> . 7. Pinzani P, Scatena C, Salvianti F, Corsini E, Canu L, Poli G, Paglierani M, Piccini V, Pazzaglia M, Nesi G, Mannelli M, <b>Luconi M*</b> . Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. <i>J Clin Endocrinol Metab.</i> 2013;98:3731-8. <b>Selected Faculty 1000</b>	3.739  3.006  3.578  3.686  4.295  4.907  6.310	4.129  3.147  4.142  6.664  7.329  5.678  5.958	26  3  5  212  26  43  25
2014 6	1. Samavat J, Facchiano E, Cantini G, Di Franco A, Alpigiano G, Poli G, Seghieri G, Lucchese M, Forti G, <b>Luconi M*</b> . Osteocalcin increase after bariatric surgery predicts androgen recovery in hypogonadal obese males. <i>Int J Obesity (Lond)</i> . 2014;38:357-63. 2. Szabó DR, <b>Luconi M</b> , Szabó PM, Tóth M, Szűcs N, Horányi J, Nagy Z, Mannelli M, Patócs A, Rácz K, Igaz P. Analysis of circulating microRNAs in adrenocortical tumors. <i>Lab Invest.</i> 2014;94:331-9. 3. Di Franco A, Guasti D, Mazzanti B, Ercolino T, Francalanci M, Nesi G, Bani D, Forti G, Mannelli M, Valeri A, <b>Luconi M*</b> . Dissecting the origin of inducible brown fat in adult humans through a novel adipose stem cell model from adipose tissue surrounding pheochromocytoma. <i>J Clin Endocrinol Metab.</i> 2014;99:E1903-12.	5.004  3.676  6.209	5.095  5.662  5.958	18  69  14

	4. Scatena C, Pinzani P, Salvianti F, Paglierani M, <b>Luconi M</b> , Mannelli M, Nesi G. Endocrine Pathology: SY08-1 Detection Of Circulating Tumor Cells In Adrenocortical Neoplasms. <i>Pathology</i> . 2014;46 Suppl 2:S13-4. 5. Samavat J, Facchiano E, Lucchese M, Forti G, Mannucci E, Maggi M, <b>Luconi M*</b> . Hypogonadism as an additional indication for bariatric surgery in male morbid obesity? <i>Eur J Endocrinol</i> . 2014;171:555-60. 6. Samavat J, Natali I, Degl'Innocenti S, Filimberti E, Cantini G, Di Franco A, Danza G, Seghieri G, Lucchese M, Baldi E, Forti G, <b>Luconi M*</b> . Acrosome reaction is impaired in spermatozoa of obese men: a preliminary study. <i>Fertil Steril</i> . 2014;102:1274-1281.	2.155  4.069  4.590	5.306  6.664  7.329	-  33  37
2015 3	1. Cantini G, Di Franco A, Samava J, Forti G, Mannucci E, <b>Luconi M*</b> . Effect of liraglutide on proliferation and differentiation of human adipose stem cells. <i>Mol Cel Endocrinol</i> 2015;402:43-50. 2. Poli G, Ceni E, Armignacco R, Ercolino E, Canu L, Baroni G, Nesi G, Galli A, Mannelli M, <b>Luconi M*</b> . 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma. <i>Oncotarget</i> 2015; 6:5695-706. 3. Mannelli M, Rapizzi E, Fucci R, Canu L, Ercolino T, <b>Luconi M</b> , Young W. Metabolism and pheochromocytoma/paraganglioma. <i>Endocr Relat Cancer</i> 2015;22:T83-T90.	3.859  5.008  4.472	4.102  5.168  5.678	13  19  8
2016 8	1. Stigliano A, Chiodini I, Giordano R, Faggiano A, Canu L, Della Casa S, Loli P, <b>Luconi M</b> , Mantero F, Terzolo M. Medical Management of Adrenocortical Carcinoma: a Consensus Statement of the Italian Society of Endocrinology (SIE). <i>J Endocrinol Invest</i> 2016; 39:103-21. 2. Mascalchi M, Falchini M, Maddau C, Salvianti F, Nistri M, Bertelli E, Sali L, Zuccherelli S, Vella A, Matucci M, Voltolini L, Lopes Pegna A, <b>Luconi M</b> , Pinzani P, Pazzagli M. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC. <i>J Cancer Res Clin Oncol</i> . 2016;142:195-200. 3. <b>Luconi M*</b> , Nreu B, Samavat J, Lorubbio M, Ognibene A, Monami M, Manucci E. Is early measurement of HbA1c useful for the prediction of treatment response in type 2 diabetes? <i>Acta Diabetol</i> , 2016;53:669-72. 4. Di Franco A, Guasti D, Squecco R, Mazzanti B, Rossi F, Idrizaj E, Gallego-Escuredo JM, Villarroya F, Bani D, Forti G, Vannelli GB, <b>Luconi M*</b> . Searching for classical brown fat in humans: development of a novel human fetal brown stem cell model. <i>Stem Cells</i> 2016;34:1679-91. 5. Cantini G, Mannucci E, <b>Luconi M*</b> . Perspectives in GLP-1 Research: New Targets, New Receptors. <i>Trends Endocrinol Metab</i> . 2016;27:427-38. 6. Poli G, Cantini G, Armignacco R, Fucci R, Santi R, Canu L, Nesi G, Mannelli M, <b>Luconi M*</b> . Metformin as a new anti-cancer drug in adrenocortical carcinoma. <i>Oncotarget</i> 2016; 7 (31): 49636-49648. 7. Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M, <b>Luconi M</b> , Jung S, Beuschlein F. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. <i>Oncotarget</i> 2016;7: 79292-79304. 8. <b>Luconi M</b> , Raimondi L, Di Franco A, Mannucci E. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting place. <i>Nutrition, Metabolism &amp; Cardiovascular Diseases</i> 2016;26:1071-1078.	2.633  3.503  3.340  5.599  10.893  5.168  5.168  3.679	4.256  4.553  4.280  6.277  12.015  5.168  5.168  4.222	26  36  3  23  42  29  19  12

2017 8	<ol style="list-style-type: none"> <li>Cantini G, Di Franco A, Mannucci E, <b>Luconi M*</b>. Is cleaved glucagon-like peptide 1 really inactive? Effects of GLP-1(9-36) on human adipose stem cells. <i>Mol Cel Endocrinol</i> 2017;439:10-15.</li> <li>Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, DE LA Villeon B, Faillot S, Hamzaoui N, Neou M, Perlemoine K, Rene-Corail F, Rodriguez S, Sibony M, Tissier F, Dousset B, Sbiera S, Ronchi C, Kroiss M, Korpershoek E, DE Krijger R, Waldmann J, Bartsch DK, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Sturm N, <b>Luconi M</b>, Mantero F, Mannelli M, Cohen R, Kerlan V, Touraine P, Barrande G, Groussin L, Bertagna X, Baudin E, Amar L, Beuschlein F, Clauer E, Coste J, Bertherat J. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>J Clin Endocrinol Metab</i>. 2017;102:923-932.</li> <li>Mascalchi M, Maddau C, Sali L, Salvianti F, Bertelli E, Zuccherelli S, Matucci EM, Borgheresi A, Raspanti C, Lanzetta M, Falchini M, Mazza E, Vella A, <b>Luconi M</b>, Pinzani P, Pazzagli M. Circulating tumor cells and microemboli can predict malignancy of pulmonary lesions. <i>J Cancer</i> 2017; 8:2223-223.</li> <li><b>Luconi M*</b>, Cantini G, Ceriello A, Mannucci E. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. <i>Int J Cardiol</i>. 2017;241:302-310.</li> <li>Perge P, Butz H, Pezzani R, Bancos I, Nagy Z, Pálóczi C, Nyíró G, Decmann A, Pap E, <b>Luconi M</b>, Mannelli M, Buzás EI, Tóth M, Boscaro M, Patócs A, Igaz P. Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. <i>Sci Rep</i>. 2017;7:5474.</li> <li>Sbiera S, Sbiera I, Ruggiero C, Doghman-Bouguerra M, Korpershoek E, de Krijger RR, Ettaleb H, Haak H, Volante M, Papotti M, Reimondo G, Terzolo M, <b>Luconi M</b>, Nesi G, Mannelli M, Libé R, Ragazzon B, Assié G, Bertherat J, Altieri B, Fadda G, ogowski-Lehmann N, Reincke M, Beuschlein F, Fassnacht M, Lalli E. Assessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma. <i>J Clin Endocrinol Metab</i>. 2017; 102:3491-3498.</li> <li>Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, <b>Luconi M*</b>, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. <i>Int J Cardiol</i>. 2017;243:86-90.</li> <li>Salvianti F, Canu L, Poli G, Armignacco R, Scatena C, Cantini G, Di Franco A, Gelmini S, Ercolino T, Pazzagli M, Nesi G, Mannelli M, Pinzani P, <b>Luconi M*</b>. New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer. <i>Oncotarget</i> 2017; 8:65525-65533.</li> </ol>	3.563 5.789 3.249 4.034 4.379 5.789 4.034 5.168	4.102 5.958 4.207 4.164 4.122 5.958 4.164 5.168	6 41 10 15 31 22 65 19	
2018 6	<ol style="list-style-type: none"> <li>Samavat J, Cantini G, Lotti F, Di Franco A, Tamburriño L, Degl'Innocenti S, Maseroli E, Filimberti E, Facchiano E, Lucchese M, Muratori M, Forti G, Baldi E, Maggi M, <b>Luconi M*</b>. Massive Weight Loss Obtained by Bariatric Surgery Affects Semen Quality in Morbid Male Obesity: a Preliminary Prospective Double-Armored Study. <i>Obesity Surgery</i> 2018;28:69-76.</li> <li>Perge P, Decmann A, Pezzani R, Bancos I, Fassina A, <b>Luconi M</b>, Canu L, Tóth M, Boscaro M, Patócs A, Igaz P. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors. <i>Endocrine</i> 2018; 59:280-287.</li> <li>Lalli E*, <b>Luconi M*</b>. The next step: mechanisms driving adrenocortical carcinoma metastasis. <i>Endocr Relat Cancer</i> 2018;25:R31-R48.</li> <li>Cantini G, Di Franco A, Mannucci E, <b>Luconi M</b>. Reply to the "Letter to the Editor" Ma Z-G, Yuan Y-P, Zhang X, Tang Q-Z. SGLT1: A potential target for human ischemic and hypertrophic heart? <i>Int J Cardiol</i>. 2018; 257:38.</li> <li>Armignacco,R, Cantini G, Canu L, Poli G, Ercolino T, Mannelli M, <b>Luconi M*</b>. Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis. <i>J Endocrinol Invest</i> 2018; 41:499-507.</li> <li>Fallahi P, Ferrari SM, Piaggi S, <b>Luconi M</b>, Cantini G, Gelmini S, Elia G, Ruffilli I, Antonelli A. The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results. <i>Immunol Res</i>. 2018; 66: 710-722.</li> </ol>	3.895 3.878 5.331 3.471 3.166 2.487	4.129 3.633 5.678 4.164 4.256 2.829	29 13 10 0 11 7	
2019 6	<ol style="list-style-type: none"> <li>Barbonetti A, D'Andrea S, Samavat J, Martorella A, Felzania G, Francavilla S, <b>Luconi M</b>, Francavilla F. Can the positive association between osteocalcin and testosterone levels be unmasked when the preeminent hypothalamic-pituitary regulation of testosterone production is impaired? The model of spinal cord-injured men. <i>J Endocrinol Invest</i> 2019;42:167-173</li> <li>Poli G, Ruggiero C, Cantini G, Canu L, Baroni G, Armignacco R, Jouinot A, Santi R, Ercolino T, Ragazzon B, Assie G, Mannelli M, Nesi G, Lalli E, <b>Luconi M*</b>. Fascin-1 is a novel prognostic biomarker associated with tumour</li> </ol>	3.166 5.789	4.256 5.789	4 12	

	<p>invasiveness in adrenocortical carcinoma. <i>J Clin Endocrinol Metab.</i> 2019;104:1712-1724</p> <p>3. Poli G, Sarchielli E, Guasti D, Benvenuti S, Ballerini L, Mazzanti B, Armignacco R, Cantini G, Lulli M, Chortis V, Arit W, Romagnoli P, Vannelli GB, Mannelli M, <b>Luconi M*</b>. Human fetal adrenal cells retain age-related stem and endocrine-differentiation potential in culture. <i>FASEB J.</i> 2019;33:2263-2277</p> <p>4. Jouinot A, Assie G, Fassnacht M, Libe R, Garinet S, Jacob L, Hamzaoui N, Neou M, Sakat J, De La Villeon B, Perlemoine K, Ragazzon B, Sibony M, Tissier F, Gaujoux S, Dousset B, Sbiera S, Ronchi CL, Kroiss M, Korpershoek E, de Krijger R, Waldmann J, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, <b>Luconi M</b>, Mannelli M, Groussin L, Bertagna X, Baudin E, Amar L, Coste J, Beuschlein F, Bertherat J. Molecular classifiers identified by integrated genomics to determine the prognosis of adrenocortical carcinoma. <i>JAMA Oncol</i> pub online Jul 11 2019</p> <p>5. Samavat J, Cantini G, Lorubbio M, Degl'Innocenti S, Adaikalakoteswari A, Facchiano E, Lucchese M, Maggi M, Saravanan P, Ognibene A, <b>Luconi M*</b>. Seminal but not serum levels of holotranscobalamin are altered in morbid obesity and correlate with semen quality: a pilot single centre study. <i>Nutrients</i> 2019 11(7). pii: E1540.</p> <p>6. Cantini G, Trabucco M, Di Franco A, Mannucci E, <b>Luconi M*</b>. Glucagon modulates proliferation and differentiation of human adipose precursors. <i>J Mol Endocrinol</i> 2019 Sep 1. pii: JME-19-0095.R2. doi: 10.1530/JME-19-0095.</p> <p>7. Armignacco R, Cantini G, Poli G, Guasti D, Romagnoli P, Mannelli M, <b>Luconi M*</b>. The adipose stem cell as a novel metabolic actor in adrenocortical carcinoma progression: evidence from an in vitro microenvironmental cross-talk model. <i>Cancers</i> 2019, 11(12), 1931; <a href="https://doi.org/10.3390/cancers11121931">https://doi.org/10.3390/cancers11121931</a></p>	5.595	5.191	14
2020 9	<p>1. Rapizzi E, Benvenuti S, Deledda C, Martinelli S, Sarchielli E, Fibbi B, Luciani P, Mazzanti B, Pantaleo M, Vannelli GB, Maggi M, Mannelli M, <b>Luconi M*</b>, Peri A. A unique neuroendocrine cell model derived from the human foetal neural crest. <i>J Endocrinol Invest</i>, 2020 43:1259-1269]</p> <p>2. Sarkadi B, Meszaros K, Krenz I, Canu L, Krokker L, Zakarias S, Barna G, Sebestyen A, Papay J, Hujber Z, Butz H, Darvasi O, Igaz P, Doczi J, <b>Luconi M</b>, Chinopoulos C, Patocs A. Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas <i>Cancers</i> 2020 12:599.</p> <p>3. Doghman-Bouguerr Ma, Finetti P, Durand N, Parise IZS, Sbiera S, Cantini G, Canu L, Hescot S, Figueiredo MOM, Komechen H, Sbiera I, Nesi G, Paci A, Al-Ghuzlan A, Birnbaum D, Baudin E, <b>Luconi M</b>, Fassnacht M, Figueiredo BC, Bertucci F, Lalli E. Cancer-testis antigen FATE1 expression in adrenocortical carcinoma is associated with a pervasive specific immune response. <i>Cancers</i> 2020, 12:689; <a href="https://doi.org/10.3390/cancers12030689">https://doi.org/10.3390/cancers12030689</a></p> <p>4. Cantini G, Di Franco A, Mannelli M, Scimè A, Maggi M, <b>Luconi M*</b>. The role of metabolic changes in shaping the fate of cancer-associated adipose stem cells. <i>Front Cell Dev Biol.</i> 2020 8:332. eCollection 2020.</p> <p>5. De Filpo G, Contini E, Serio V, Valeria A, Chetta M, Guasti D, Bani D, Mannelli M, Rapizzi E, <b>Luconi M</b>, Maggi M, Ercolino T, Canu L. Germline mutation in KIF1β gene associated to loss of heterozygosity. Usefulness of Next Generation Sequencing in the genetic screening of patients with "pheochromocytoma". <i>Int J Endocrinol</i> 2020 May 30;2020:3671396.</p> <p>6. Tamburrino L, Marchiani S, Muratori M, <b>Luconi M</b>, Baldi E. Progesterone, spermatozoa and reproduction: an updated review. <i>Mol Cell Endocrinol</i> 2020 516:110952</p> <p>7. Creemers S, Feelders R, Valdes N, Ronchi C, Volante M, van Hemel BM, <b>Luconi M</b>, Ettaieb M, Mannelli M, Chiara MD, Fassnacht M, Papotti M, Kerstens M, Nesi G, Haak H, van Kemenade F, Hofland L. THE IGF2 METHYLATION SCORE FOR ADRENOCORTICAL CANCER: AN ENSAT VALIDATION STUDY. <i>Endocr Relat Cancer</i> 2020 27:541-550.</p> <p>8. Di Dalmazi G, Altieri B, Scholz C, Sbiera S, <b>Luconi M</b>, Waldman J, Kastelan D, Ceccato F, Chiodini I, Arnaldi G, Osswald A, Reincke M, Beuschlein F, Sauer S, Fassnacht M, Appenzeller S, Ronchi CL. RNA-SEQUENCING AND SOMATIC MUTATION STATUS OF ADRENOCORTICAL TUMORS: NOVEL PATHOGENETIC INSIGHTS. <i>J Clin Endocrinol Metab.</i> 2020 Dec 1;105(12):dgaa616.</p> <p>9. Cantini G, Canu L, Armignacco R, Salvianti F, De Filpo G, Ercolino T, Nesi G, Maggi M, Mannelli M, Pinzani P, <b>Luconi M*</b>. Prognostic and monitoring value of circulating tumour cells in adrenocortical carcinoma: a preliminary monocentric study. <i>Cancers</i> 2020, 12(11), 3176</p>	3.166	4.256	0
	<p>6.612</p> <p>6.612</p> <p>5.206</p> <p>2.287</p> <p>3.563</p> <p>5.331</p> <p>5.455</p> <p>6.162</p>	<p>6.639</p> <p>6.639</p> <p>6.684</p> <p>3.257</p> <p>4.102</p> <p>5.678</p> <p>5.958</p> <p>6.639</p>	<p>6</p> <p>6</p> <p>2</p> <p>0</p> <p>1</p> <p>0</p> <p>4</p> <p>3</p>	

2021	8	<p>1. Crona J, Baudin E, Terzolo M, Chrisoulidou A, Angelousi AG, Ronchi CL, Lamas C, Nieveen van Dijkum E, Ceccato F, Borson-Chazot F, Reimondo G, Tiberi GA, Ettaieb H, Kiriakopoulos A, Canu L, Kastelan D, Osher E, Yiannakopoulou E, Arnaldi G, Assie G, Paiva I, Bourdeau I, Newell-Price J, Nowak KM, Romero MT, De Martino MC, Bugalho MJ, Sherlock M, Vantyghem MC, Dennedy MC, Loli P, Rodien P, Feelders RA, de Krijger RR, Van Slycke S, Aylwin S, Morelli V, Vroonen L, Shafigullina Z, Bancos I, Trofimiuk-Müldner M, Quinkler M, <b>Luconi M</b>, Kroiss M, Naruse M, Igaz P, Mihai R, Della Casa S, Berruti A, Fassnacht M, Beuschlein F. ENSAT Registry-Based Randomized Clinical Trials for Adrenocortical Carcinoma. <i>Eur J Endocrinol.</i> 2021 Feb;184(2):R51-R59. doi: 10.1530/EJE-20-0800.</p> <p>2. Catalano R, Giardino E, Treppiedi D, Mangili F, Morelli V, Elli FM, <b>Luconi M</b>, Mannelli M, Spada A, Arosio M, Mantovani G, Peverelli E, The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. <i>Cancer Letters</i> 2021, 497:77-88</p> <p>3. Mascalchi M, <b>Luconi M</b>. Invited Editorial for: Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial. <i>Chest</i> 2021 May;159(5):1699-1700.</p> <p>4. Assis Gonçalves D, Ribeiro V, Gualberto A, Fiel Peres F, <b>Luconi M*</b>, Gameiro J*. COVID-19 and obesity: an epidemiologic analysis of the Brazilian data. <i>Int J Endocrinol</i> 2021 May 5;2021:6667135. doi: 10.1155/2021/6667135.</p> <p>5. Cantini G, Fei L, Canu L, De Filpo G, Ercolino T, Nesi G, Mannelli M, <b>Luconi M</b>. Circulating Fascin 1 as a promising marker in adrenocortical cancer: a very preliminary monocentric study. <i>Front Endocrinol</i> 2021 Jun 23;12:698862. doi: 10.3389/fendo.2021.698862. eCollection 2021.</p> <p>6. Di Franco S, Pellegata N, <b>Luconi M*</b>, Stassi G. Editorial: Stem Cells in Endocrine Tumors. <i>Front. Endocrinol.</i> Jun 28;12:722790. doi: 10.3389/fendo.2021.722790. eCollection 2021.</p> <p>7. Cantini G, Fei L, Canu L, Lazzeri E, Sottilli M, Francalanci M, Angelotti ML, De Filpo G, Ercolino T, Gelmini S, Mangoni M, Nesi G, Mannelli M, Maggi M, <b>Luconi M*</b>. The role of CXCL12/CXCR4 axis in anti-cancer activity of the peroxisome proliferator-activated receptor gamma ligand rosiglitazone in adrenocortical carcinoma. <i>J Personalized Medicine</i> 2021, 11(11), 1097</p> <p>8. Canu L, Puglisi S, Berchialla P, De Filpo G, Brignardello F, Schiavi F, Ferrara AM, Zovato S, <b>Luconi M*</b>, Pia A, Appeteccchia M, Arvat E, Letizia C, Maccario M, Parasiliti-Capriano M, Altieri B, Faggiano A, Modica R, Morelli V, Arosio M, Verga U, Pellegrino M, Petramala L, Concistrè A, Paola Razzore, Ercolino T, Rapizzi E, Maggi M, Stigliano A, Burrello J, Terzolo M, Opocher G, Mannelli M, Reimondo G. A multicenter epidemiological study on second malignancy in non-syndromic pheochromocytoma/paraganglioma patients in Italy. <i>Cancers (Basel)</i>. 2021 Nov 20;13(22):5831</p>	6.664	6.664	2		
2022	5	<p>1. Grau-Bové C, González-Quilen C, Cantini G, Nardini P, Espina B, Bani D, Terra X, Blay MT, Rodríguez-Gallego E, <b>Luconi M*</b>, Ardévol A*, Pinent M. GLP1 exerts paracrine activity in the intestinal lumen of human colon. <i>Int J Mol Sci.</i> 2022 Mar 24;23(7):3523</p> <p>2. De Filpo G, Cantini G, Rastrelli G, Vannini G, Ercolino T, <b>Luconi M</b>, Mannelli M, Maggi M, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience. <i>J Endocrinol Invest</i> 2022 Jan;45(1):149-157</p> <p>3. Sottilli M, Filardi T, Cantini G, Cosmi L, Murano S, <b>Luconi M</b>, Lenzi A, Crescioli C. Human cell-based anti-inflammatory effects of rosiglitazone. <i>J Endocrinol Invest</i> 2022 Jan;45(1):105-114.</p> <p>4. Provenzano A, Chetta M, De Filpo G, Cantini G, La Barbera A, Nesi G, Martinelli S, Rapizzi E, <b>Luconi M</b>, Maggi M, Mannelli M, Ercolino T, Canu L. Novel germline PHD variant in a metastatic pheochromocytoma patient in absence of polycythemia. Aug 17;58(8):1113. doi: 10.3390/medicina58081113.</p> <p>5. <b>Luconi M</b>, Sogorb MA, Markert UR, Benfenati E, May T, Wolbank S, Roncaglioni A, Schmidt A, Straccia M, Tait S. Human-based new approach methodologies in developmental toxicity testing: a step ahead from the state-of-the-art with a feto-placental organ-on-a-chip platform. <i>International Journal of Environmental Research and Public Health</i> 2022 Nov 28;19(23):15828. doi: 10.3390/ijerph192315828</p>	6.01	6.01	0		

2023 7	<p>1. Fei L, Cantini, Nocentini A, Nardini P, Catarinicchia S, Canu S, Ercolino T, Quartararo G, Nesi G, Gacci M, Maggi M, Hantel C, Mannelli M, Supuran CT, <b>Luconi M*</b>. Carbonic Anhydrases III and IX are new players in the crosstalk between adrenocortical carcinoma and its altered adipose microenvironment. <i>J Endocrinol Invest.</i> 2023 Jan 16. doi: 10.1007/s40618-023-02008-4.</p> <p>2. <b>Luconi M*</b>, Cantini G, van Leeuwaarde RS, Roebaar R, Fei L, Propato AP, Santi R, Ercolino T, Mannelli M, Canu L, de Krijger RR, Nesi G*. Prognostic Value of Microscopic Tumor Necrosis in Adrenal Cortical Carcinoma. <i>Endocr Pathol.</i> 2023 Mar 23. doi: 10.1007/s12022-023-09760-6. Epub ahead of print.</p> <p>3. Ruggiero C, Tamburello M, Rossini E, Zini S, Durand N, Cantini G, Cioppi F, Hantel C, Kiseljak-VassiliadesK, Wierman ME, Landwehr LS, Weigand I, Kurlbaum M, Zizoli D, Turtoi A, Yang S, Berruti A, <b>Luconi M</b>, Sigala S, Lalli E. FSCN1 as a new druggable target in adrenocortical carcinoma. <i>Int J Cancer.</i> 153(1):210-223. doi: 10.1002/ijc.34526</p> <p>4. Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragozo MCBV, Canu L, <b>Luconi M</b>, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nöltig S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchiella P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. <i>Lancet Diabetes Endocrinol.</i> 2023 11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6.</p> <p>5. Cantini G, Niccolai E, Canu L, Di Gloria L, Baldi S, Propato AP, Fei L, Nannini G, Puglisi S, Nesi G, Ramazzotti M, Amedei A, <b>Luconi M*</b>. The intratumoral microbiota modulates adrenocortical cancer responsiveness to mitotane. <i>Endocrine-Related Cancer, in press 2023 DOI: <a href="https://doi.org/10.1530/ERC-23-0094">https://doi.org/10.1530/ERC-23-0094</a>.</i></p> <p>6. Catalano R, Altieri B, Angelousi A, Arosio M, Bravi F, Canu L, Croci GA, Detomas M, Esposito E, Ferrante E, Ferrero S, Fuss CT, Kaltsas G, Kimpel O, Landwehr LS, <b>Luconi M</b>, Morelli V, Nesi G, Nozza E, Sbiera S, Serban AL, Ronchi CL, Mantovani G, Peverelli E. High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study. <i>Int J Mol Sci.</i> 2023 Nov 21;24(23):16573</p> <p>7. Mannelli M, Bartoloni B, Cantini G, Nencioni E, Magherini F, <b>Luconi M</b>, Modesti A, Gamberi T, Fiaschi T. STAT3 Signalling Drives LDH Up-Regulation and Adiponectin Down-Regulation in Cachectic Adipocytes. <i>Int J Mol Sci.</i> 2023 Nov 15;24(22):16343.</p>	4.256	4.256	3	
2024 4	<p>1. Cantini G, Quartararo G, Ghezzi N, Gonçalves DA, Fei L, Propato AP, Galtarossa L, Lucchese M, Maggi M, <b>Luconi M*</b>. Visceral adipose tissue adiponectin predicts excess weight loss after bariatric surgery in females with severe obesity. <i>Int J Obes (Lond).</i> 2024 Feb;48(2):247-253. doi: 10.1038/s41366-023-01406-1.</p> <p>2. Canu L, Sparano C, Naletto L, De Filpo G, Cantini G, Rapizzi E, Martinelli S, Ercolino T, Cioppi F, Fantoni A, Zanatta L, Terreni A, Mannelli M, <b>Luconi M</b>, Maggi M, Lotti F. Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy. <i>Front Endocrinol (Lausanne).</i> 2024 Jan 10;14:1320722. doi: 10.3389/fendo.2023.1320722.</p> <p>3. Cioppi F, Cantini G, Ercolino T, Chetta M, Zanatta L, Nesi G, Mannelli M, Maggi M, Canu L, <b>Luconi M*</b>. Targeted NGS Approach and Its Clinical Application in Adrenocortical Cancer, <i>Eur J Endocrinol.</i> 2024 Jul 2;191(1):17-30. doi: 10.1093/ejendo/lvae077</p> <p>4. Martinelli S, Cantini G, Propato AP, Bani D, Guasti D, Nardini P, Calosi L, Mello T, Bechmann N, Danza G, Villanelli F, Canu L, Maggi M, Mannelli M, Rapizzi E, <b>Luconi M*</b>. The 3D in vitro Adrenoid cell model recapitulates the complexity of the adrenal gland. <i>Sci Rep.</i> 2024 Apr 5;14(1):8044. doi: 10.1038/s41598-024-58664-w.</p>	4.900	4.900	2	

2025	<p>1. Sojat AS, Rance B, Neuraz A, Fassnacht M, Beuschlein F, Robledo M, <b>Luconi M</b>, Vassiliadi D, Stell A, Igaz P, Dugic B, Marina LV, Burgun A, Kastelan D, Assie G; European Network for the Study of Adrenal Tumors (ENSAT)/COST Action Harmonisation (CA 20122) consortium. How ready are endocrine scientists to share retrospective clinical data for research: a perspective from the European Network for the Study of Adrenal Tumors. <i>Eur J Endocrinol.</i> 2025 Mar; 27;192(4):491-509. doi: 10.1093/ejendo/lvaf005.</p> <p>2. Fei L, Propato AP, Lotti G, Nardini P, Giusti D, Polvani S, Bani D, Galli A, Casini D, Cantini G, Chiaramonti D, <b>Luconi M</b>. Tailor-made Biochar enhances the anti-tumour effects of butyrate-glycerides in colorectal cancer. <i>Biomed Pharmacother.</i> 2025 Mar; 184:117900. doi: 10.1016/j.biopha.2025.117900</p> <p>3. Catalano R,....<b>Luconi M</b>...., Peverelli E. Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. <i>Cell Commun Signal.</i> 2025 Mar 4;23(1):119. doi: 10.1186/s12964-025-02115-0</p> <p>4. <b>Luconi M*</b>, Cantini G, Crescioli C. Repurposing glucose lowering drugs for cancer therapy. <i>Trends in Cancer.</i> 2025 Jul; 11(7):691-710. doi: 10.1016/j.trecan.2025.04.010.</p> <p>5. De Fazio G, Scolari F, Fancelli S, Polvani S, Lavacchi D, Picariello L, Tubita A, <b>Luconi M</b>, Antonuzzo L, Galli A, Pillozzi S. Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. <i>Front Oncol.</i> 2025 in press.</p>	5.800	5.800	
		6.900	6.900	1
		8.500	8.500	
		14.300	14.300	
		3.300	3.300	

#### NATIONAL JOURNALS

1. **Luconi M**, Baldi E, Forti G. Ruolo degli estrogeni nella regolazione del sistema riproduttivo maschile. *Repronews*, Settembre 2003
2. **Luconi M**, Baldi E, Forti G. Estrogeni e riproduzione maschile. *Biologi Italiani*, Novembre-Dicembre 2003
3. Canu L, Armignacco R, Poli G, Cantini G, Ercolino T, Mannelli M, **Luconi M\***. Caratterizzazione genomica del carcinoma surrenalico. *L'Endocrinologo* 2016; 17:293–299. review

#### NON-MEDLINE JOURNALS

1. Baldi E., M. Luconi, L. Bonaccorsi, G. Forti. Nongenomic effects of progesterone on spermatozoa: relevance to sperm function. *Current Topics in Steroid Research*, Vol. 2, p.119-125, 1999. NO IF no PubMed
2. Luconi M., Bonaccorsi L., Forti G., Baldi E. Signal transduction mechanisms in human spermatozoa: from physiology to possible new therapeutic applications. *Emerging Therapeutic Targets* 4: 239-253, 2000. NO IF no PubMed
3. Luconi M., E. Baldi, G. Forti (2005) Rapid responses to estrogens in human spermatozoa. In: *Reproduction, Nutrition, Development*; vol 45 (2) pages 201-202 (rivista non impattata, non in medline)
4. Luconi M. (2006) Rapid responses to estrogens. In the Special issue of Reproductive Medicine: "ESTROGENES and MALE FERTILITY". Guest editors : Jean- Pierre Dadoune & Serge Carreau; John Libbey EUROTEXT; vol 8 (2):119-127 (rivista non impattata, non in medline)

#### EDITOR

Guest Editor of the Research Topic Issue of *Frontiers in Endocrinology Cancer Endocrinology* 2019: "Cancer Stem Cells in Endocrine Tumors" G. Stassi, M. Luconi, S. Di Franco, N. Pellegata

Guest Editor of the Research Topic Issue of *Cancers* 2022 "Targeting Tumor Microenvironment as a Novel Promising Approach in Adrenal Tumors" M. Luconi, G. Cantini, M. Kroiss

#### BOOK CHAPTERS


- [1] **Luconi**, Cs. Krausz, R. Casano, M. Mancini, G. Forti, E. Baldi (1994): Il Platelet-activating factor come possibile modulatore della funzionalità dello spermatozoo umano. In: La medicina della Riproduzione, eds. C. Foresta, A. Isidori, C. Scandellari, Panda Edizioni, pp. 93-96.
- [2] Krausz Cs., Bonaccorsi L., **Luconi M.**, Forti G., Fuzzi B., Criscuoli L., Pellegrini S., Baldi E. (1994): Responsiveness to progesterone of spermatozoa is significantly related to the fertilization rate in IVF cycles. In: *Frontiers in Endocrinology*, vol 9, pp. 277-279.

- [3] Forti G., Baldi E., **Luconi M.**, Krausz Cs., Casano R., Bonaccorsi L., Maggi M., Finetti G., Mancini M., Falsetti C., Gervasi G. (1994): Effects of progesterone on human spermatozoa: a model for non-genomic actions of steroids. In: Frontiers in Endocrinology, vol 9, pp. 259-260. Italian Endocrine Society: 1994 Award Lecture.
- [4] Bonaccorsi L., **Luconi M.**, Forti G., Baldi E. (1995): L'inibizione dell'attività tirosino chinasica riduce la fase di plateau dell'aumento del calcio indotto dal progesterone negli spermatozoi umani. In: Infertilità maschile: Approccio Terapeutico Razionale, eds. C. Foresta e C. Scandellari, CLEUP, Padova, pp. 81-85.
- [5] Baldi, Krausz Cs., Bonaccorsi L., Maggio P., **Luconi M.**, Criscuoli L., Fuzzi B., Pellegrini S., Forti G. (1997) Metodiche di valutazione della capacità fertilizzante degli spermatozoi umani. In: Corso di Aggiornamento in Andrologia Medica. Syllabus. pp. 50-53. Firenze 6-7 Febbraio 1997.
- [6] Baldi E., **M. Luconi**, L. Bonaccorsi, P. Pecchioli., G. Forti. (1998) Metodiche di valutazione del potere fertilizzante degli spermatozoi umani. In: Corso di Perfezionamento in Andrologia. Syllabus. pp. 212-214. Firenze Febbraio-Maggio 1998.
- [7] Baldi E., **M. Luconi**, L. Bonaccorsi, G. Forti. Nongenomic effects of progesterone on spermatozoa: mechanisms of signal transduction and clinical implications. *Pediatric Pathology and Molecular Medicine*, vol 18, n 4-5, 417-431, 1998.
- [8] Baldi E., **Luconi M.**, Muratori M., Maggi M., Mancini M., Forti G. (1999) Regolazione della capacità fertilizzante dello spermatozoo. In: La Riproduzione Maschile: fisiopatologia e clinica. Eds. C. Foresta e C. Scandellari, CLEUP, Padova, pp. 95-101.
- [9] **Luconi M.**, Forti G., Baldi E. (2001) Meccanismi di trasduzione del segnale nella regolazione della motilità spermatica. In: Fisiopatologia delle funzioni gonadiche. Eds. C. Foresta e C. Scandellari, CLEUP, Padova, pp. 193-203.
- [10] Baldi E., **Luconi M.**, Forti G., (2002) Il trattamento in vitro delle astenozoospermie. In: La Medicina della Riproduzione: aspetti clinici e terapeutici. Eds. C. Foresta e C. Scandellari, CLEUP, Padova, pp. 105-111.
- [11] **Luconi M.**, Forti G., Baldi E. (2002) Swimming with spermatozoa: the molecular bases of sperm motility. In Proceedings of the 9<sup>th</sup> International Symposium on Spermatology. Eds. G. van der Horst, D. Franken, R. Barman, T. Barman, S. Dyer., Monduzzi, Bologna, Italy.
- [12] **Luconi M.**, Baldi E., Forti G., (2003) Meccanismi di regolazione della motilità spermatica: Fisiologia e possibili applicazioni terapeutiche. In: Il percorso clinico-diagnostico della coppia infertile. Eds. C. Foresta e C. Scandellari, CLEUP, Padova, pp. 149-154.
- [13] Baldi E., **M. Luconi** (2003) La terapia in vitro dell'astenozoospermia In: Corso Residenziale di Aggiornamento in Andrologia. Syllabus. pp. 53-57. Firenze 21-25 Gennaio 2003.
- [14] **Luconi M.**, Baldi E. (2003) Membrane estrogen receptors in human spermatozoa: an example of non-classical steroid receptor located to the membrane. Chap.23, pp187-192. *The Identities of Membrane Steroid Receptors*. Ed. C.S. Watson. Kluwer Academic Publishers.
- [15] Morelli A., Vignozzi L., Mancina M., Filippi S., **Luconi M.**, Marini M., Forti, G., Maggi M. (2004) Regolazione androgenica dell'espressione genica e dell'attività di PDE5 : In: Andrologia e Riproduzione Eds. C. Foresta e A. Ferlin, CLEUP, Padova, pp. 29-36.
- [16] **Luconi M.**, Forti G., Baldi E. (2005) Approccio terapeutico in vitro all'astenospermia. In: Le alterazioni gonadiche:aspetti fisiologici e clinici . Eds. C. Foresta, A. Lenzi, A. Ferlin, CLEUP, Padova, pp. 423-427
- [17] **Luconi M.**, E. Baldi, G.F. Doncel. Physiology and Pathophysiology of sperm motility. In "Male infertility: Diagnosis and Treatment". Eds Oehninger SC and Kruger TF.. Taylor and Francis, Informa London, UK 2007. **Invited review**; pp.13-33
- [18] **Luconi M.**, Rochira V. Estrogen Resistance. In. Encyclopedia of Molecular Mechanisms of Disease. 2<sup>nd</sup> Edition. Ed Lang F. Springer. Springer-Verlag GmbH Berlin Heidelberg 2009. **Invited review**. ISBN 978-3-540-67136-7
- [19] **Luconi M.**, Corona G, Facchiano E, Lucchese M, Maggi M. Section B: Bariatric Surgery, Obesity and fertility "Fertility and testosterone improvement in male patients after bariatric surgery". Handbook of Fertility: Nutrition, Diet, Lifestyle and Reproductive Health, First Edition. 2015. Pp.109-117 **Invited review**.
- [20] Maggi M, Morelli A, **Luconi M.**, Lotti F., Lucchese M, Facchiano E, Corona G. Hypogonadism and Obesity Minimally Invasive Bariatric and Metabolic Surgery: Principles and Technical Aspects, M. Lucchese, N. Scopinaro (eds.). Springer International Publishing Switzerland 2015 DOI 10.1007/978-3-319-15356-8\_5; pp35—42. **Invited review**
- [21] Cantini G, Trabucco M, Dicembrini I, Mannucci E, **Luconi M.** Intestinal Hormones in HORMONAL SIGNALING IN BIOLOGY & MEDICINE (ACADEMIC PRESS/ELSEVIER) 2020. **Invited review**.
- [22] Rapizzi E, Abate A, Tamburello M, **Luconi M.**, Sigala S. Preclinic and translational research in Adrenal Malignancies in Primary Adrenal Malignancies- Updates in Surgery Series, Springer 2024; pp.167-176. **Invited review**.

**PATENTS**

1. "Processo per aumentare la motilità degli spermatozoi e spermatozoi a motilità superiore così ottenuti". Inventors: **LUCONI M, BALDI E, FORTI G**; Università di Firenze, Pat. Applic. N. FI99A000171, 26/07/99. National Patent.
2. "Process for the improvement of spermatozoa fertilization activity". Inventors: **LUCONI M, BALDI E, FORTI G; SERONO Applied Research Systems ARS Holding N.V.**, 01/02/2001. PCT/EP00/07108. WO 01/07021 A2 International Patent. Extension in USA, Japan and Canada.
3. "Uso alimentare e medicale, per umano e animale, di carbone attivo per l'assorbimento del glucosio". Inventors: **LOTTI G, LUCONI M, CHIARAMONTI D, CANTINI G, CASINI D, PROPATO AP-** "Consorzio per la ricerca e la dimostrazione sulle energie rinnovabili dal titolo /UNIFI Lab Congiunto BIODELIVERY- P12203IT00, 13/08/2025 National Patent

La sottoscritta firma e allega fotocopia di documento di identità in corso di validità.



## **CURRICULUM VITAE**

*Dichiarazione sostitutiva di certificazione e dichiarazione sostitutiva di notorietà ai sensi del D.P.R 445/28 12 2000*

Il sottoscritto Massimo D'Amico nato a [REDACTED]  
residente a [REDACTED]

consapevole delle responsabilità penali cui può andare incontro, in caso di dichiarazioni mendaci, ai sensi e per gli effetti di cui all'art. 78 del D.P.R. 445/2000 e consapevole che ai sensi dell'art. 12 del Regolamento UE 2018/879 (GDPR), la presente dichiarazione sarà pubblicata sul sito web dell'amministrazione Trasparente, sotto la propria responsabilità

**dichiara  
ai sensi degli art. 46 e 47 del DPR 445/2000**

## **INFORMAZIONI PERSONALI**

**Nome:** Massimo D'Amico

**Indirizzo:** XXXXXXXX

**Telefono:** XXXXXXXX

**Email:** XXXXXXXX

**Nazionalità:** Italiana

**Data di nascita:** [REDACTED]

## **ESPERIENZA LAVORATIVA**

Dal 02/04/2025- in corso FUNZIONARIO, SETTORE SCIENTIFICO E TECNOLOGICO  
PRESSO UNIVERSITÀ DEGLI STUDI DI FIRENZE

Dal 20/03/2023 –al 23/03/2025  
BORSISTA DI RICERCA AOUC-AZIENDA OSPEDALIERA UNIVERSITARIA  
CAREGGI (FIRENZE) SODGASTROENTEROLOGIA CLINICA

Dal 02/01/2014 – al 29/04/2022  
DIRETTORE TECNICO CONTRATTO DI TECNICO CHIMICO CAT. C2 CRO DI.V.A.L  
TOSCANA SRL Sesto Fiorentino, Italia

Dal 2010 – al 2012  
ASSEGNISTA DI RICERCA DIPARTIMENTO DI MEDICINA SPERIMENTALE E  
CLINICA-UNIVERSITÀ DEGLI STUDI DI FIRENZE

Dal 2006 – al 2009  
IMPIEGATO TECNICO-TD E PARZIALE DIPARTIMENTO DI MEDICINA  
SPERIMENTALE E CLINICAUNIVERSITÀ DEGLI STUDI DI FIRENZE

Dal 2002 – al 2006  
ASSEGNISTA DI RICERCA DIPARTIMENTO DI MEDICINA SPERIMENTALE E  
CLINICA-UNIVERSITÀ DEGLI STUDI DI FIRENZE

Dal 1993 – al 2001  
ASSISTENTE SOCIO-SANITARIO A.N.F.F.A.S. FIRENZE

## **ISTRUZIONE E FORMAZIONE**

1989 Diploma di Scuola Secondaria presso Liceo Classico M.T.  
Cicerone Sala Consilina (SA), Italia

1999 Laurea in Scienze Biologiche presso Università degli Studi di  
Firenze

1999-2000 Tirocinio post-laurea per l'abilitazione alla professione di  
biologo Università degli Studi di Firenze

2000 Abilitazione all'esercizio della professione di  
biologo (II sessione) Università degli Studi di Firenze

2000-2003 Dottorato di Ricerca in Oncologia Sperimentale e Clinica  
Università degli Studi di Firenze

## **CAPACITÀ E COMPETENZE PERSONALI**

*Acquisite nel corso della vita e  
della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

MADRELINGUA : Italiana  
ALTRE LINGUA : Inglese

Capacità di lettura: C1  
Capacità Ascolto: B1  
Capacità Produzione orale: B2  
Capacità Interazione orale: B1  
Capacità di scrittura: C1

## **CAPACITÀ E COMPETENZE TECNICHE**

Microsoft Word / Microsoft Excel / Microsoft Powerpoint / E-mail use /  
Internet user / Origin Pro: proficient at scientifical data processing / FlowJo  
program / ModFit LT / Image JFiji / Clampfit/Clampex / Data Analyzer

**PATENTE O PATENTI:** Patente auto B

Il sottoscritto firma e allega fotocopia di documento di identità in corso di validità

Firenze, 06/10/2025

Firma



## CURRICULUM VITAE



*Dichiarazione sostitutiva di certificazione e dichiarazione sostitutiva dell'atto di notorietà ai sensi del D.P.R. 445/28.12.2000  
(allegare copia non autenticata di documento di identità del sottoscrittore in corso di validità)*

La sottoscritta Serena Pillozzi nato a [REDACTED]  
[REDACTED]

---

consapevole delle responsabilità penali cui può andare incontro, in caso di dichiarazioni mendaci, ai sensi e per gli effetti di cui all'art. 76 del D.P.R. 445/2000 e consapevole che, ai sensi dell'art. 13, del Regolamento UE 2016/679 (GDPR), la presente dichiarazione sarà pubblicata sul sito web dell'amministrazione in apposita sezione di Amministrazione Trasparente, sotto la propria responsabilità

**dichiara  
ai sensi degli artt. 46 e 47 del DPR 445/2000**

## INFORMAZIONI PERSONALI

Nome	PILLOZZI SERENA
Indirizzo	*****
Telefono	*****
Email	*****
Nazionalità	italiana
Data di nascita	[REDACTED]

## ESPERIENZA LAVORATIVA

01-10-2023-in corso RTD-B presso Università di Firenze

Dal 01-07-2022-ad oggi *Assegnista di ricerca MED-06* presso DMSC, Università di Firenze

Dal 01-05-2019 al 31-05-2022  
AOU Careggi-SODc Oncologia Medica  
Largo Brambilla 3, Firenze  
*Borsa di Studio*

01-07-2015 al 30-06-2018  
Università di Firenze  
Dipartimento di Medicina Sperimentale e Clinica  
Largo Brambilla 3, Firenze  
*RICERCATORE universitario a t.d.- t. pieno MED/04 (art. 24 c.3-a L. 240/10) di tipo A*

01-01-2014 al 01-12-2014  
Associazione Noi per Voi per il Meyer in collaborazione con Dipartimento di Oncoematologia, Azienda Ospedaliero-Universitaria Meyer, Firenze.

*Collaboratore a progetto-* Attività di ricerca sul progetto “ Nuovi tools per il superamento della chemioresistenza in pazienti pediatrici affetti da leucemie linfoblastiche acute.

29/12/2010 a 28/12/2013  
Università di Firenze  
Dipartimento di Medicina Sperimentale e Clinica  
Largo Brambilla 3, Firenze  
*RICERCATORE universitario a t.d.- t. pieno MED/04 (art. 1 c.14 L. 230/05) di tipo A*

01/01/2009-31/12/2009  
Università di Firenze  
Dipartimento di Patologia e Oncologia Sperimentali  
Viale Morgagni 50, Firenze

**ASSEGNISTA DI RICERCA /YED/04-Attività di ricerca sul progetto “Physical and functional interaction between integrins and hERG1 channels in cancer cells”**

**ISTRUZIONE E FORMAZIONE**

01/01/2006-31/12/2008

Università di Firenze

*Borsa di dottorato di ricerca in Oncologia Sperimentale e Clinica- XXI ciclo*  
Titolo della tesi " Identificazione di nuovi fakori prognostici in neoplasie emopoietiche: analisi in vivo mediante reinocolo in topi nod/scid e tramite studio di opportuni modelli animali geneticamente modificati."

01/03/2003-28/02/2005

Università di Firenze

Dipartimento di Patologia e Oncologia Sperimentali  
Viale Morgagni 50, Firenze

**ASSEGNISTA DI RICERCA MED-04-Attività di ricerca sul progetto “Ion channels and cancer”**

01/03/2001-28/02/2003

Università di Firenze

Dipartimento di Patologia e Oncologia Sperimentali  
Viale Morgagni 50, Firenze

**ASSEGNISTA DI RICERCA /MED/04-Attività di ricerca sul progetto “Role of potassium channels in leukemia cells differentiation”**

Dicembre 2017

Ministero dell'Istruzione, dell'Università e della ricerca

*Idoneità abilitazione scientifica nazionale, Professore seconda fascia -Settore Concorsuale 06/A2 Patologia Generale*

01/01/2006-31/12/2008

Università di Firenze

**DOTTORATO DI RICERCA in ONCOLOGIA SPERIMENTALE E CLINICA**  
Dottore di ricerca in Oncologia Sperimentale e Clinica

aa 1993/94-1997/98

Università di Firenze

Corso di Laurea in Scienze Biologiche-indirizzo fisiopatologico, Università di Firenze.

Laurea

**CAPACITÀ E COMPETENZE PERSONALI**  
*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

MADRELINGUA

italiano

ALTRE LINGUA

INGLESE

Buono, B2

Buono, B2

Buono, B2

**CAPACITÀ E COMPETENZE TECNICHE**

*Con computer, attrezzature specifiche, macchinari, ecc.*

Ottima conoscenza dei programmi fondamentali del pacchetto Office (Word, ExGel, Power Point) e dei principali browsers per la navigazione internet. Conoscenza approfondita dei softwares per l'analisi di immagine (Adobe Photoshop, Image J) e buona conoscenza dei softwares per l'analisi di dati biologici (Calculusyn, Origin).

PATENTE O PATENTI

B

La sottoscritta firma e allega fotocopia di **documento di identità** in corso di validità.

Firenze, 3 Ottobre 2025

